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CHAPTER 1
INTRODUCTION

Inflammation is the process by which proteins and cells accumulate at a
site of tissue damage or infection (for a review, see Kovacs and Frazier-Jessen
1994). The activation of the cells at these sites leads to the removal of necrotic
tissue and either regeneration of the normal tissue or replacement with scar
tissue. The inflammatory process is designed to provide a rapid mechanism by
which the host can respond to the invasion of foreign materials and return to a
homeostatic equilibrium. Excessive or inadequate activation of the system can
have serious effects, as can the failure of inactivation mechanisms. In these
instances, the end result is wounds that never heal, wounds that heal poorly, or
wounds that heal too much (Figure 1). Wounds that never heal include most
neoplasms. Wounds that heal poorly are represented by cutaneous ulcers, a
common complication in diabetics and other individuals with circulatory
problems.

Wounds that heal too much result in an overproduction of

connective tissue that severely limits and often destroys the functionality of the
organ tested.

In the skin, this results in severe scarring, such as keloid

formation. In other organs such as lung, liver, and peritoneum, the end result is
fibrosis and/ or adhesion formation. Fibrosis and adhesion formation in the
peritoneal cavity can lead to formation of bowel strictures (Fabri and
Rosemurgy 1991; Krebs and Goplerud 1987), a life-threatening consequence
that requires immediate medical intervention.

Furthermore, adhesion

formation is an important pathological consequence of endometriosis, one of
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PATHOBIOLOGY OF WOUND REPAIR
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Figure 1. The Pathobiology of Wound Repair.

the ma1or causes of infertility (Haney 1993).

Therefore, a more accurate

understanding of the regulation of the inflammatory events would aid in
prevention of these pathologic consequences or the development of effective
therapeutic agents.
Studies have shown that one immune cell population essential for
resolution of the wound is the macrophage (Leibovich and Ross 1975). The
wound macrophage is not only responsible for the phagocytosis of foreign
material/ debris, but probably most important, the secretion of a wide
assortment of mediators known as cytokines that aid in cellular recruitment,
stimulation of new matrix production and proliferation of fibroblasts (Kovacs
1991). While the fibroblast itself is critical in the production of new matrix
components, it is essentially under the control of these macrophage-derived
mediators.

One cytokine that has been shown to significantly effect the

outcome of wound healing is monocyte chemotactic protein-1 (MCP-1). As its
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name implies, this cytokine is a potent chemotactic and activating factor for
monocytes and macrophages (Rollins, Walz, and Baggiolini 1991; Yoshimura
and Leonard 1990; Yoshizuka et al. 1989; Zachariae et al. 1990).
Most studies involving the immune response to inflammation to date
have utilized male animals, and those involving females have ignored the cyclic
fluctuation of sex steroid hormones associated with the estrus cycle (Dresser
1992). Recent studies suggest that endogenous female hormones may affect a
number of processes involved in the immune response. Since hormones are
likely to play an integrative role in the development of the response to injury,
endocrine disorders can impair host defenses to infection. It is, therefore,
relevant to understand how hormones regulate the initiation and subsequent
course of the inflammatory reaction.

This is especially important when

considering drug therapy, as it is necessary to have an understanding of the
potential modulatory influences of these hormones.

Hypothesis
Estrogen modulates connective tissue deposition in the peritoneal cavity
in response to talc-induced injury.

This modulation of connective tissue

deposition occurs, in part, through the decreased migration of macrophages
into the inflammatory site via inhibition of the macrophage chemoattractant
protein, JE.
Specific Aims
Aim 1:

To develop a murine model of peritoneal adhesion formation in
the peritoneal cavity and a quantitative means for assessing it.

Rationale:
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Peritoneal fibrosis is a common clinical problem whose treatment
is currently limited to surgical intervention. Current assessment
techniques are limited to ranking of adhesions following visual inspection. A model system with a means of more accurate assessment would allow for analysis of therapeutics in the treatment of
this complication.

Aim2:

To examine the effect of estrogen on connective tissue deposition
in a murine model of peritoneal adhesion formation.

Rationale:

Estrogen plays a role in connective tissue remodeling in reproductive organs and it has also been shown to have effects on the
inflammatory response, the event preceding connective tissue deposition. It is, therefore, conceivable that estrogen can modulate
connective tissue remodeling in response to an inflammatory
event.

Aim3:

To examine the effect of estrogen on gene expression of JE, a
macrophage chemotactic factor, in primary culture macrophages
and macrophage cell lines.

Rationale:

Macrophage recruitment, via chemotactic factors such as JE, is
critical to the resolution of an inflammatory stimulus. As estrogen
has previously been shown to alter production of other macrophage-derived cytokines, it is conceivable that estrogen could alter
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JE gene expression and thus modulate the ultimate outcome of
inflammation.

CHAPTER2
REVIEW OF THE RELATED LITERATURE

The Inflammatory Response
The inflammatory response can be divided into a series of overlapping
stages: acute vascular, acute cellular, chronic cellular, and resolution (Kovacs
and DiPietro 1994). This response is triggered by trauma, infection, tissue
necrosis, or immune reaction, which leads to the dilation of blood vessels
causing the leakage of fluid from precapillary arterioles. Acute changes in
blood flow pattern lead to margination of neutrophils along the vascular surface
of the endothelial cells, followed by the directed migration of neutrophils
through the endothelial cell monolayer into the connective tissue below.
Depending on the degree of infection or tissue damage, this process may be
sufficient to remove debris and to restore normal tissue structure. However, a
chronic inflammatory infiltrate of macrophages and lymphocytes is usually
necessary to remove bacteria and necrotic tissue. When the damage is more
extensive, normal tissue is replaced in the resolution phase by scar tissue, a
result of the proliferation of fibroblasts and the depositing of connective tissue
proteins.

Aberrant Wound Healing
The return to normal tissue structure and function following a local
inflammatory event depends o the degree of damage to the tissue and the
6
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ability of cells within the tissue to regenerate. In the lung, for example, after the
removal of the epithelium, a "competition" arises between reepithelialization
and fibrosis (Hascheck and Witschi 1979; Haslett and Henson 1988; Terzaghi,
Nettesheim, and Williams 1978). In the absence of inhibitory signals, the
aberrant production of these mediators sustains the connective tissue
architecture.
The overproduction of connective tissue can permanently damage or
severely limit the functionality of the organ involved. Examples of overhealing
in the skin include hypertrophic scarring, keloid formation, and third degree
burns. In other organs, such as the lung, liver and peritoneal cavity, this results
in fibrosis and/ or adhesion formation (see Figure 1, Chapter 1).

The Peritoneum and Adhesion Formation
The peritoneal cavity is the largest cavity in the body and the lining of its
surface area equals that of the skin. The lining of the peritoneal cavity, called
the peritoneum, is composed of a single layer of mesothelium that rests on a
thin layer of fibroelastic connective tissue (Figure 2, Part A). In the absence of
pathology, the peritoneal cavity contains a minimal amount of peritoneal fluid
(Padawer 1973).
The irritation and inflammation of the peritoneum is known as
peritonitis and is almost always preceded by some kind of intervention into the
peritoneal cavity. During this inflammatory state, there is an outpouring of
exudate which contains fibrinogen and may cause the intraperitoneal tissues to
adhere to their neighbors (Myllarniemi et al. 1966). While the majority of these
fibrinous adhesions are transient, some become fibrous by the ingrowth of
fibroblasts and blood vessels (Jackson 1958).
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mesothelium

(A)

basement membrane
abdominal musculature

disrupted mesothelium

(B)

connective tissue/ fibroplasia

abdominal musculature

Figure 2. The Peritoneal Membrane (A) under normal, noninflammatory
conditions; (B) after injury (fibrosis) with increased connective tissue deposition
along with migration of fibroblasts and macrophages into the submesothelial
space.

Although the process of healing follows similar patterns in all wounds,
peritoneal healing is different from skin wound healing in that healing of the
mesothelium takes place throughout the whole surface and even extended
defects of the peritoneum are completely resolved within 7-8 days (Raftery
1973a; Raftery 1973b; Raftery 1973c). In contrast, epithelialization of the skin
starts from the wound edges and is a slower, more prolonged process.
Within a short time period post-injury, a fibrin network appears in the
abdominal cavity (Myllarniemi et al. 1966).

The local coagulative and
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fibrinolytic properties of the peritoneum largely determine the final state of
adhesion formation (Gervin, Puckett, and Silver 1973; Porter, Ball, and Silver
1971). If fibrinolysis is adequate or the damage is moderate, adhesions may
disappear (Buckman et al. 1976). However, if the injury is extensive or the
irritating substance cannot be cleared, extensive adhesions can appear within 24
hours.

Fibroblasts then proliferate into the fibrin and turn it into fibrous

adhesions (Myllarniemi et al. 1966) (Figure 2, Part B).

Fully developed

adhesions may be observed from 10 days to 2 weeks (Welte, Albinus, and
Dominick 1973).
An important factor in adhesion formation is the chemotactic, phagocytic
and fibrogenic functions of PMNs and macrophages (Curran and Clark 1964).
Macrophages are especially critical in the final resolution of tissue debris and
completion of healing, a process that ends in the formation of connective tissue
matrix and mesothelial syncytium (Bryant et al. 1988).

Causes of Peritoneal Adhesions
The production of scar tissue within the peritoneal cavity can result from
surgery, infection, introduction of foreign materials, or intraperitoneal
immunotherapy regimens to treat abdominal tumors. It is also a complication
for renal dialysis patients undergoing continuous ambulatory peritoneal
dialysis (CAPD) and for women who suffer from endometriosis.

Surgical Intervention
Surgical procedures in the abdominal cavity can often result in the
formation of peritoneal adhesions. These adhesions can result from tissue
ischemia, excessive bleeding, and thermal injury during the surgical procedure.
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As a result of tissue injury, post-surgical resident peritoneal macrophages
secrete factors that either suppress or enhance the proliferation peritoneal tissue
repair cells, in addition to modulating the morphology and secretion of
extracellular matrices by these cells (Rodgers and DiZerega 1992).
Furthermore, various kinds of irritants which are only slowly absorbed
such as glove powders, surgical materials, materials applied intraperitoneally
for investigative purposes or for the treatment of peritonitis can induce
granulation tissue and adhesions. If the inflammatory state turns chronic, the
proliferation of fibroblasts and connective tissue formation continues and after
several months appears as fibrosis.
Talc, a form of silica, is used during the construction of synthetic gloves.
This substance, which is poorly, if at all, cleared by the immune system, induces
a strong granulomatous foreign body reaction (Eismann, Seelig, and Womack
1947). Many cases of peritoneal adhesion formation are the result of talc
contamination secondary to abdominal surgery (Henderson et al. 1978; Kus et
al. 1979).

Intraperitoneal Immunotherapy
The use of intraperitoneal immunotherapy for the treatment of tumors
localized in the peritoneal cavity has gained widespread popularity in recent
years. In these instances, intraperitoneal (i.p.) therapy affords a higher concentration of infused biological response modifiers than does intravenous
administration. One method of i.p. immunotherapy involves the culture of
autologous peripheral blood leukocytes with interleukin-2 (IL-2) to generate
lymphokine-activated killer (LAK) cells. LAK cells are extremely effective at
killing tumor cells in vitro (Grimm et al. 1982). The i.p. infusion of LAK cells
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and additional IL-2 has had promising preliminary results in combating ovarian

tumors in vivo (Urba et al. 1989). One of the complications arising form LAK
cell/IL-2 therapy is the development of peritoneal fibrosis (Lotze, Custer, and
Rosenberg 1986; Steis et al. 1990; Urba et al. 1989). Dense adhesions form within
the peritoneal cavity, initially around the catheter site. These adhesions prevent
the LAK cells from reaching their tumor targets. Patients must then be removed
from therapy, and in some cases, undergo surgery to lyse adhesions. The
development of these adhesions has not been clearly elucidated, but could be
due to the production of fibrogenic mediators by the LAK cells (Kovacs et al.
1989; Kovacs et al. 1990) or by IL-2-stimulated resident peritoneal cells (Kovacs
and Neuman 1991; Kovacs, Stedum, and Neuman 1994) in response to the
treatment, the tumor cells themselves, either alone or in combination. It would,
therefore, be of interest to further investigate each of these areas.

Continuous Ambulatory Peritoneal Dialysis
and Peritoneal Adhesions
Continuous ambulatory peritoneal dialysis (CAPD) is an important and
effective method of treatment for end-stage renal disease.

However, this

therapy is characterized by a nearly 50% chance of patients developing
recurrent peritonitis (Golper and Hartstein 1986; Schneble et al. 1992). CAPD
patients present with peritoneal alterations characterized by a diffuse
thickening of the peritoneal membrane due to an increased amount of
connective tissue (Daugirdas et al. 1986; Gandhi et al. 1980). This fibrotic
response remains one of the major causes of "dropout" of CAPD patients, due to
a decrease in ultrafiltration capacity by the peritoneal membrane (Carozzi 1990;
Nolph et al. 1984). Peritoneal macrophages play an important role in the

pathology observed in these patients.

12
This macrophage population is

characterized by a highly activated, immature phenotype, such as those seen in
chronic inflammatory diseases (Betjes et al. 1993).

During episodes of

peritonitis, these macrophages secrete high levels of cytokines such as IL-1,
TNF-a (Douvdevani et al. 1993; Fieren, Bernd, and Bonta 1990; Fieren et al.
1991), IL-6, and IL-8 (Lin, Lin, and Huang 1993). The presence of such high
levels of inflammatory cytokines can result in a chronic inflammatory state and
thus lead to the fibrotic response observed in the peritoneal cavity of these
patients.

Endometriosis and Peritoneal Adhesions
Endometriosis occurs when normal endometrial tissue grows in extrauterine locations, such as the peritoneal cavity. This ectopic endometrial tissue
may eventually lead to the formation of scar tissue or peritoneal adhesions.
Besides causing extreme pain, endometriosis is though to be one of the major
causes of infertility. Further complications include bowel obstruction, which
must be treated surgically (Krebs and Goplerud 1987).
Some of the modifications seen within the pelvic cavity in patients with
endometriosis include an increase in the production of cytokines by infiltrating
leukocytes. These cytokines include IL-1 (Fakih et al. 1987), IL-6 (Buyalos et al.
1992), TNF-a (Eisermann et al. 1988; Halme 1989), and PDGF (Halme 1988). In
addition, peritoneal fluid from endometriosis patients has higher chemotactic
activity for macrophages and monocytes than peritoneal fluid from normal
patients, although the identity of the chemotactic factor has not yet been
deduced (Leiva et al. 1993).
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The source of increased cytokines in the peritoneal cavity of
endometriosis patients could be from ectopic endometrium. This tissue has the
potential to elaborate a wide variety of cytokines, since the endometrium is a
site of active cytokine production (Tabibzadeh 1991). In addition, peritoneal
macrophages, which secrete all of the above-mentioned mediators, are present
in very high numbers in the peritoneal fluid of endometriosis patients
(Badaway et al. 1984; Halme et al. 1983). Not surprisingly, the number of
macrophages present in these patients directly corresponds with the severity of
the disease (Olive, Weinberg, and Haney 1985).
The cyclic variations in hormone concentrations are responsible for most
of the pathological modifications observed in endometriosis patients. Other
investigators have shown that cytokine levels and cell populations in the uterus
fluctuate during the estrus cycle and that sex hormones regulate these changes
(De, Sanford, and Wood 1993; De, Sanford, and Wood 1992; De and Wood 1990;
Olive, Weinberg, and Haney 1985). Furthermore, an increase in macrophage
and PMN chemotactic activity is observed in the peritoneal fluid of
endometriosis patients (Leiva et al. 1993). This chemotactic activity is decreased
below that of normal patients in endometriosis patients receiving hormonal
treatment.

All of these observations suggest that the development and

progression of endometriosis by inflammatory cells may be hormonally
regulated.

Inflammation and Wound Healing
As discussed above, it is the inflammatory cells present within the
damaged tissue site that are responsible for repair and resolution. Of the cell
populations present, the macrophage and the fibroblast play direct roles in the
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synthesis and remodeling of connective tissue elements necessary to return the
damaged tissue to a functional state.

Macrophages
Monocytes constitute 3-8% of the circulating leukocyte population and
mature into connective tissue macrophages on migration out of the circulatory
system into specific extravascular compartments.

After derivation from

precursors in the bone marrow, monocytes remain in the circulation for 1-2
days before they differentiate into macrophages.
Macrophages are long-lived, highly motile phagocytic cells with large
numbers of lysosomes, endocytotic vacuoles, and intracellular vesicles
containing indigestible material. Macrophages ingest extracellular material by
phagocytosis and pinocytosis. These internalized components are digested by
lysosomal enzymes to clear them from the extracellular environment. On
activation, the number of lysosomes per cell increases, as does the amount of
hydrolytic enzyme per lysosome, to facilitate the digestion of material taken up
by phagocytosis. Under certain conditions, such as the invasion of foreign
material, macrophages can form multinucleated giant cells resulting from the
fusion of several macrophages. These giant cells can remain in the tissue for
extended periods of time and are thought to act as barricades that surround
foreign material, thus separating it from normal tissue.
In culture, as well as in vivo, macrophages adhere to surfaces of cells and
to extracellular matrix elements, and are able to migrate. In addition to making
directed and random movements as cellular entities, macrophages can extend
pseudopods in an ameboid fashion to reach out and explore their environment.
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Tissue macrophages were initially named for the specific tissues in which
they were identified, for example, alveolar or pulmonary macrophages of the
lung. Although the macrophages from different tissues share certain "generic"
characteristics, some characteristics are tissue specific. For example, because of
high concentration of oxygen in the lung, alveolar macrophages have a higher
capacity to produce reactive oxygen metabolites than do macrophages from
other tissues.
In addition to being migratory and phagocytic, macrophages are also
highly secretory, producing a variety of mediators that range from cytokines
and prostaglandins to connective tissue elements (for a review, see Nathan
1987). These factors include enzymes (Werb and Gordon 1975a; Werb and
Gordon 1975b) and cytokines.
Over the past two decades, activated macrophages have been shown to
produce several mediators which play direct or indirect roles in inflammatory
and fibrotic processes.

These cytokines, which will be referred to as

proinflammatory and fibrogenic, include IL-1 (Schmidt et al. 1982), IL-8 (Rot
1993), JE/MCP-1 (Rollins, Walz, and Baggiolini 1991), TNF-a (Beutler et al.
1985), PDGF (Shimakado et al. 1985), FGF (Baird, Morm'ede, and B:ohlen 1985),
and TGF-P (Assoian et al. 1987) are discussed later in the text.

Fibroblasts
Fibroblasts are mesenchymal cells present in most organs which play a
crucial role in repair processes. Fibroblasts are the most abundant of connective
tissue cell types. Although they may be dormant for prolonged periods of time,
these cells are capable of returning to the cell cycle on stimulation by
appropriate environmental cues. In response to injury, resident fibroblasts in
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the surrounding tissue proliferate and then migrate into the wound site (Clark
1993). Once within the wound, they produce high levels of collagen, as well as
a variety of other extracellular matrix molecules (Kleinman, Klebe, and Martin
1981), and deposit these molecules into the local milieu. Overproduction of
collagen by fibroblasts is felt to be the result of high levels or continued
production of cytokines and other inflammatory mediators (Kovacs 1991).
Macrophages are known to produce cytokines that modulate growth and
collagen synthesis by fibroblasts. PDGF, for example, is one such macrophagederived factor which induces resident fibroblasts to proliferate (Ross and Raines
1990).

In addition, fibroblasts are intimately involved in the feedback

mechanisms during the inflammatory response as they also secrete
inflammatory cytokines (Cochran, Reffel, and Stiles 1983; Elias, Reynolds, and
Lentz 1990; Elias et al. 1989).

Cytokines
Cytokines are soluble protein mediators secreted by cells which regulate
immunological and inflammatory events.

Generally, cytokines are low

molecular weight secretory proteins that are produced transiently and locally.
These mediators are extremely potent, working at picomolar concentrations and
interacting with high affinity cell surface receptors that are specific for each
cytokine or cytokine family. Studies have shown that a number of cytokines
can induce fibroblast proliferation and connective tissue deposition (see Kovacs
1991, for a review). These cytokines include TNF-a, IL-1, IL-8, JE/MCP-1,
PDGF and

TGF-~,

all of which can have an important role in determining the

outcome of an inflammatory response by their ability to recruit and activate
local macrophage populations.
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Proinflammatory Cytokines
Proinflammatory, or early inflammatory cytokines are thought to initiate
a cascade of events which can lead to fibrosis. A subset of these mediators has
been reported to be present in the abdominal cavity. The presence of pelvic
pathology, ranging from endometriosis to ovarian cancer, showed a positive
correlation with elevatedproduction of cytokines (Buyalos et al. 1992; Halme et
al. 1988) and fibronectin (Kauma et al. 1988) by peritoneal lavage cells.
Furthermore, elevated levels of fibrogenic cytokines are present in peritoneal
fluid from patients given intraperitoneal infusion of lymphokine-activated killer
cells and interleukin-2 (IL-2) to combat ovarian tumors (Kovacs and Urba,
unpublished observation), in mice given intraperitoneal IL-2 (Frazier-Jessen and
Kovacs, unpublished observation) or murine peritoneal macrophages treated
with IL-2 in vitro (Kovacs, Van Stedum, and Neuman 1994).

Of these

cytokines, IL-1, TNF-a and JE/MCP-1 are discussed below.

Interleukin-1
Interleukin-1 (IL-1) was first described in the 1940s as endogenous
pyrogen, a substance in acute exudate fluid, which, when administered in vivo,
induced fever (reviewed in (Dinarello 1984)).

Since then, a multitude of

biological actions have been attributed to this cytokine (Oppenheim et al. 1986).
IL-1 is felt to be the body's key mediator of acute responses to microbial
invasion, immunological reaction, inflammation and tissue injury.

The

biological effects of IL-1 are manifested in nearly every tissue and organ system.
It is one of the first mediators to be synthesized in the course of an

inflammatory event and is thought to initiate a cascade of effects. IL-1 is
chemotactic for monocytes and lymphocytes (Hunninghake et al. 1986) and
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mitogenic for fibroblasts (Bonin, Fici, and Singh 1989; Schmidt et al. 1982). In
addition, IL-1 initiates collagen synthesis by increasing transcription of types I,
III (Canalis 1986) and IV collagen (Matsushima et al. 1985). Therefore, fibrosis
and deposition of abnormal proteins in tissues appears to be mediated, in part,
by IL-1.

Tumor Necrosis Factor-a
Tumor necrosis factor-a (TNF-a) is a multifunctional cytokine that plays
a pivotal role in immune and inflammatory reactions. It was first described as
an endotoxin-induced serum protein that caused tumor-specific hemhorragic
necrosis of tumor cells (Carswell et al. 1975). Although macrophages and
monocytes are the major source of TNF-a (Mannel, Moore, and Mergenhagen
1980; Matthews 1981), other cell types can also synthesize this cytokine. TNF-a
is identical to cachectin, the serum factor responsible for the wasting syndrome
associated with chronic infections and cancer (Beutler et al. 1985). TNF-a is
important in the initiation and subsequent remodeling phases of the
inflammatory response. Studies have suggested that TNF-a is chemotactic for
both PMNs and monocytes (Ming, Bersani, and Mantovani 1987), although this
function may be indirectly mediated by TNF-a. TNF-a has also been reported
to have growth stimulatory effects on fibroblasts (Thornton et al. 1990) and can
induce angiogenesis(Leibovich et al. 1987). Overproduction of TNF-a is linked
to chronic inflammatory states and fibrosis.

JE/MCP-1
The JE gene, first identified in mouse 3T3 cells, is a PDGF-inducible early
response gene (Cochran, Reffel, and Stiles 1983). Unlike other early response
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genes, JE encodes a secreted glycoprotein with cytokine-like properties. The
human homologue of JE has been cloned and identified as monocyte
chemotactic protein-1 (MCP-1) (Rollins et al. 1990; Yoshimura et al. 1989).
JE/MCP-1 belong to a recently identified family of low molecular weight
secreted proteins involved in the recruitment of cells during the inflammatory
response that include IL-8 and monocyte inflammatory protein (MIP) (for a
review, see Oppenheim et al. 1991).

In vitro, JE is a potent monocyte

chemoattractant and activating factor (Rollins, Walz, and Baggiolini 1991;
Yoshimura and Leonard 1990; Yoshizuka et al. 1989).

In vivo, JE causes

monocyte accumulation (Zachariae et al. 1990) and induces monocyte-mediated
tumoricidal activity (Rollins and Sunday 1991).
Because recruitment of cells, especially those of the monocyte and
macrophage lineage, is critical to the outcome of a healing tissue, regulation of
JE could ultimately affect the outcome of a wound healing response.
Investigators have shown that JE is present in several models of lung fibrosis
(Brieland et al. 1993; Flory, Jones, and Warren 1993) and in atherosclerotic
lesions (Koch et al. 1993; Nelken et al. 1991; Takeya et al. 1993; Yla-Herttuala et
al. 1991; Yu et al. 1992). Not surprisingly, macrophages are found to be the
predominant cell types producing JE in these instances of aberrant wound
healing (Koch et al. 1993). These data suggest that, while JE production may be
critical for the healing wound, sustained production of JE, especially by resident
macrophages, results in overhealing.

Fibrogenic Cytokines
In contrast to the above-mentioned cytokines, PDGF and TGF-P are
thought to be highly fibrogenic, as they are able to directly trigger the
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proliferation of fibroblasts and/ or stimulate the production of connective tissue
(for a review, see (Kovacs 1991)). Aberrant production of these mediators has
been demonstrated in animal models of lung fibrosis (Kovacs and Kelley 1985).
Additional studies have shown that these cytokines are produced locally, at the
site of tissue damage in the lung (Kovacs, Oppenheim, and Young 1986) as well
as in the peritoneal cavity of patients undergoing peritoneal dialysis
(Shimakado et al. 1985) or intraabdominal cancer therapy (Kovacs and Urba,
unpublished observations).

Platelet-Derived Growth Factor
Platelet-derived growth factor (PDGF) is a cationic, heat stabile protein of
approximately 30 kD.

Although PDGF was first discovered in the alpha

granules of platelets (Shimakado et al. 1985), it has since been found in a wide
variety of cell types, of both normal and transformed phenotype. These cell
types include monocytes (Martinet et al. 1986), macrophages (Shimakado et al.
1985), endothelium (Ross, Raines, and Bowen-Pope 1986; Starksen et al. 1987),
smooth muscle cells (Sjolund et al. 1988) and fibroblasts (Paulsson et al. 1987).
Interestingly, macrophage-derived PDGF was first isolated from cells obtained
from peritoneal dialysis patients (Shimakado et al. 1985). PDGF is the primary
source of mitogenic activity in plasma for mesenchymal connective tissueforming cells (Kohler and Lipton 1974; Ross et al. 1974; Rutherford and Ross
1976). In addition, it is highly chemotactic for mesenchymal cells (Grotendorst
et al. 1981; Grotendorst et al. 1982; Seppa et al. 1982) and to a lesser degree
PMNs and mononuclear cells (Deuel et al. 1982; Williams, Antoniades, and
Goetzl 1983). PDGF not only stimulates collagen production (Canalis 1981), but
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it also increases collagenase activity (Bauer et al. 1985). Thus, PDGF is thought
to play a central role in tissue remodeling and wound healing.

Transforming Growth Factor-~
Transforming growth

factor-~

(TGF-~)

is a homodimeric protein

originally defined for its ability to reversibly induce a transformed phenotype
and anchorage-independent growth of normal fibroblasts (Roberts et al. 1981).
There five known isoforms of

TGF-~.

Of these, only types 1,2 and 3 have been

demonstrated in mammalian tissue (type 4 is from chicken and type 5 is from
frog).

Although the biological activities of most of these isoforms are

indistinguishable in vitro, their sites of synthesis and in vivo localization are
often distinct. While platelets are the major storage site of TGF-~ (Assoian et al.
1983), macrophages, lymphocytes and fibroblasts also produce

TGF-~

Roberts, and Sporn 1986; Assoian and Sporn 1986; Kehrl et al. 1986).

(Anzano,

TGF-~

has

been shown to stimulate fibroblast proliferation (Hill et al. 1986) and synthesis
of extracellular matrix proteins, including collagen molecules I, II, V,
fibronectin, and other various proteoglycans (Ignotz and Massague 1986; Madri,
Pratt, and Tucker 1988; Varga, Rosenbloom, and Jimenez 1987). In addition,
TGF-~

is a chemoattractant for both fibroblasts and inflammatory cells both in

vitro and in vivo (Mustoe et al. 1987; Postlethwaite et al. 1987; Roberts et al.
1986; Wahl et al. 1987).

TGF-~-like

activity has been found in several ovarian

cancer cell lines (Berchuck et al. 1990) and in the peritoneal lavage fluid of
ovarian cancer patients. Our laboratory has shown that the peritoneal lavage
fluid from patients undergoing IL-2/LAK cell therapy contains both TGF-~ and
PDGF (Kovacs and Urba, unpublished observation) and that human peripheral
blood lymphocytes and rat resident peritoneal macrophages stimulated with IL-
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2 produce both cytokines (Kovacs et al. 1989; Kovacs and Neuman 1991; Kovacs,
Stedum, and Neuman 1994). Thus, growth factors such as

TGF-~

and PDGF are

present in the peritoneal cavity at sites adjacent to mesenchymal cells and may
play a critical role in the development of peritoneal fibrosis.

The Immune-Endocrine Axis
It has become widely accepted that the endocrine and immune systems

interact extensively to regulate each other (Grossman 1985). In response to
stress, there is an activation of the hypothalamic-pituitary-adrenal axis leading
to the output of glucocorticoids.

Besides having dramatic effects on

metabolism, these glucocorticoids have strong immunosuppressive and
antiinflammatory properties. A less-studied set of steroid hormones with
potentially significant effects on the immune system are the gonadal steroids.
This lack of research is surprising, considering that it has long been known that
a sexual dimorphism exists as far as the immune response is concerned (AnsarAhmed, Penhale, and Talal 1985). Furthermore, pregnancy causes a wide
variety of immune function-altered events to occur (Carr 1990).
Steroid hormones are theorized to work by binding to nuclear receptors
located within the cell (Figure 4) (Murdoch and Gorski 1991). In this model,
free steroid dissociates across the plasma membrane and is transported to the
nucleus where it binds to the unoccupied steroid receptor. Once bound to its
ligand, the steroid receptor is now able to bind to specific regions of DNA,
known as steroid response elements, and thereby affect transcription of target
genes.
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Figure 3. Immune Cell Populations Involved in the Wound Healing Response.

Glucocorticoids
Glucocorticoids have long been known to suppress immune functions
and are thus thought to help regulate both the cellular and humoral immune
responses under normal and stressing conditions.

Physicians have used

glucocorticoids in the clinical management of inflammatory and immunologic
diseases for many years. One of the caveats of using glucocorticoids is their farreaching and potentially harmful immuno-suppressive actions. Conversely,
pathologic alterations in glucocorticoid secretion can seriously affect the
immune response.
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Figure 4. Proposed Mechanism of Action of Steroids.

Effects on Fibroblasts
As previously discussed, fibroblasts are responsible for the repair and
maintenance of the extracellular matrix. Collagen is the major connective tissue
protein synthesized by fibroblasts. Studies have shown that glucocorticoids
inhibit collagen synthesis in normal and inflamed tissues (Cockayne et al. 1986).
In addition, migration and proliferation of fibroblasts into wound sites are
inhibited by glucocorticoids (Durant, Duval, and Homo-Delarche 1986).
Because collagen is the major extracellular matrix protein in vertebrates, it is
important that if glucocorticoids are administered for anti-inflammatory
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purposes, that they are given at the lowest possible dose, so that inflammation
is inhibited while minimizing the inhibitory effects of fibroblast collagen
synthesis of normal connective tissues.

Effects on Macrophages
Glucocorticoids have profound effects on both macrophage function and
activation (Guyre and Munck 1989). In vivo administration of glucocorticoids
leads to a dramatic depletion and subsequent redistribution of monocytes from
the periphery to the bone marrow (Hahn et al. 1980). Furthermore, cellmediated immune reactions are generally inhibited (Weston, Mandel, and
Yeckley 1973). Both inflammatory response and wound healing capabilities of
macrophages are inhibited in vivo (Guyre and Munck 1989). These in vivo
observations correlate with in vitro findings showing diminished functional
response in macrophage antigen processing and presentation (Hirschberg et al.
1982), inhibition of monocyte chemotaxis (Rinehart et al. 1975), inhibition of
phagocytosis (Shepard, Kanish, and Stahl 1985), and suppression of
lymphokine-induced giant cell formation (Galindo 1984).

Furthermore,

glucocorticoids also inhibit prostaglandin release (Wahl and Winter 1984). All
of the above-mentioned phenomena are critical in the development and
resolution of the inflammatory response.

Estrogen
Estrogen is essential for the development and maintenance of the female
reproductive tract (Carr 1990). Estrogen in produced in the ovary during the
reproductive years, in larger quantities at the onset of puberty and throughout
menarche until menopause. Estrogens are synthesized by the aromatization of
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androgens (dihydroepiandrostenedione and testosterone). Three estrogens are
produced by the ovaries, two of which are produced in relative abundance. Of
these, the most potent estrogen is

estradiol-17~

(E 2 ).

Estrogen levels vary

throughout the reproductive cycle and are under the control of follicle
stimulating hormone (FSH) and luteinizing hormone (LH). Estrogen secretion
is low during the early follicular phase and increases prior to the midcycle
gonadotrophin surge, peaking and then dropping off at the surge.
Estrogens stimulate DNA synthesis and cell proliferation in the female
reproductive organs and other target tissue sites. In the reproductive tissues,
estrogens are involved in the inflammatory and tissue remodeling events that
occur throughout the menstrual cycle. For example, estradiol decreases the
amount of collagenase produced by rat uterine cervical fibroblasts in culture
(Sato et al. 1991). In addition, estrogen-progestogen therapy in postmenopausal
women has been shown to decrease type Ill collagen production (Kashnikova,
Grozdova, and Panasiuk 1991). Estradiol replacement for postmenopausal
women is very effective at treating bone loss (Ralston, Russell, and Gowen 1990)
probably due to its ability to inhibit the release of TNF-a, a potent stimulator of
bone resorption. Furthermore, one of the factors associated with an increased
risk in the development of cardiovascular disease in women is the onset of
menopause. Epidemiological studies have shown that estrogen replacement
reduces the risk of development of cardiovascular disease (Eaker and
W.P.Castelli 1987; Knopp 1988; Paganini-Hill, Ross, and Henderson 1988;
Stampfer et al. 1991; Sullivan et al. 1990) by poorly understood mechanisms.
Estrogen receptors have been found in monocytes/macrophages
(Gulshan, McCruden, and Stimson 1990; Weusten et al. 1986), lymphocytes
(Cohen et al. 1983), mast cells (Cocchiara et al. 1990), and resident mesenchymal
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cells (Malet et al. 1991), suggesting that estrogens can directly alter the immune
response by modulating of both proliferation of these cell types and their
cytokine production profile.

Thus, there is a link between estrogen and

connective tissue production and estrogen and the immune response.
Further evidence for the role of sex steroids in the fibrotic process is that
connective tissue diseases, such as scleroderma and systemic lupus
erythematosus, are significantly more prevalent in women of childbearing age
than in postmenopausal women and men (Czirjak et al. 1989; Steen 1990; Steen
and Medsger 1990). These disease states are often altered during pregnancy,
when steroid hormone levels are markedly elevated. In addition, certain types
of arthritis are modulated by female sex hormones (Holmdahl and Jansson
1988).
Only a handful of studies have reported on the effects of gonadal steroids
on the expression of cytokine genes in purified immune cell populations. Hu
and coworkers (Hu, Mitcho, and Rath 1988) showed that adherent peritoneal
cells obtained from intact female rats secreted greater amounts of IL-1 than cells
from male or ovariectomized (OVX) female rats. The increased production of
IL-1 is restored following E2 replacement in OVX animals.

IL-1~

mRNA

expression in LPS-stimulated human monocytes (Polan et al. 1989) was elevated
marginally in response to low physiological levels of E2 and inhibited markedly
after treatment with high doses of E2 • The doses required to diminish LPSinduced expression of

IL-1~

mRNA were 10

-7

-5

to 10 , well above the

physiological range. The requirement for such high doses suggests that ~ may
not be utilizing specific high affinity receptors, but rather low affinity estrogen
binding sites reported to be present on peripheral blood mononuclear cells
(Ranelletti et al. 1988; Wada et al. 1992). At physiological levels, E2 had marked
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inhibitory affects on the production of TNF-a by human peripheral blood
monocytes from postmenopausal women (Ralston, Russell, and Gowen 1990).
Similar affects were not observed in monocytes obtained from men or
premenopausal women. This difference may be due to the relative levels of
estrogen receptors in men, premenopausal and postmenopausal women.
Hence, a majority of the studies revealed that normal physiological levels of E2
enhanced cytokine mRNA expression and high physiological (and
pharmacological) doses turned off expression. Because of the design of these
experiments, it is not clear whether the observed effects of E2 on cytokine gene
expression were direct or indirect.
A recent report identified the locations of four estrogen response
elements (ERE), which serve to modulate gene expression, in the 5' flanking
region of the murine interferon-y (IFN-y) gene (Fox, Bond, and Parslow 1991),
showing for the first time that estrogen could have a direct effect on the control
of expression of a cytokine gene. They also reported that estrogen acted
synergistically with concavalin A to trigger expression of IFN-y mRNA in
murine splenocytes. In view of the pleiotropic effects of IFN-y on the function
of immune cells, including the activation of macrophages to produced a variety
of cytokines, stimulation of IFN-y production by E2 could have marked
stimulatory effects on the immune system.
Modulation of the production of these cytokines and connective tissue
proteins by E2 in vivo could have profound effects on the deposition of
peritoneal adhesions (Figure 5). Estrogen may act at one or more levels to
trigger connective tissue deposition. We and others have shown that estrogen
triggers lymphocytes to produce IFN-y ((Fox, Bond, and Parslow 1991); Kovacs
and Mott, unpublished observation). Furthermore, elevated expression of IFN-y
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can trigger resident macrophages to produce proinflammatory and fibrogenic
cytokines. These mediators, in turn, can enhance the proliferation of fibroblasts
and the synthesis of collagen. In addition, since ER are present in circulating
mononuclear cells (Wada et al. 1992; Weusten et al. 1986) and macrophages
(Gulshan, McCruden, and Stimson 1990), estrogen may act directly on
macrophage activation. Fibroblasts can be triggered by estrogen to produce
both fibrogenic cytokines and connective tissue proteins.

Thus, systemic

elevation of estrogen could have both direct and indirect stimulatory effects on
connective tissue production.
Investigation of the control of expression of cytokine genes and the role
these mediators play in the development of peritoneal fibrosis is of immediate
clinical relevance. In addition, furthering our understanding of the role of
female sex steroids in this process will help to explain the mechanisms by which
females are more susceptible to autoimmune diseases and connective tissue
disorders. The results of these studies are also directly relevant to the control of
aberrant wound healing, which is the hallmark of a variety of diseases
including atherosclerosis and pulmonary fibrosis.
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Figure 5. Potential Effects of Estrogen on Cells Involved in the Wound Healing
Response.

CHAPTER3
ABDOMINAL WALL THICKNESS AS A MEANS OF ASSESSING
PERITONEAL FIBROSIS IN MICE

Abstract
Herein we describe a method for the quantitative assessment of
connective tissue deposition within the peritoneal cavity. Female C57BL/ 6
mice (8-10 weeks) were given a single intraperitoneal injection of varying
concentrations of talc (100 mg, 50 mg, 30 mg, 20 mg) in 1 ml of PBS or PBS
alone. After 14 days, animals were killed. Adhesion formation was measured
by the standard method of Myllarniemi et al. (Myllarniemi et al. 1966), namely a
gross visual inspection of the peritoneal cavity. This analysis gave a crude
assessment of connective tissue deposition in the abdominal cavity but did not
allow one to distinguish more subtle differences between intermediate dosage
groups. In addition, a histological evaluation was performed. For the latter
method, portions of the abdominal wall of mice were fixed and processed for
histological analysis using Masson's Trichrome stain which allows for
differentiation of connective tissue components. The thickness of connective
tissue between the parietal peritoneum and the underlying abdominal wall
muscle was measured.

A dose-dependent increase in connective tissue

deposition was observed in talc-treated animals compared to saline control
animals. A differential cell count of the peritoneal exudate cells (PEC) showed
that there was no change in cell populations in talc treated animals (compared
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to control animals). Given the above results, the measurement of connective
tissue thickness was found to give the most accurate assessment of peritoneal
fibrosis than other previously used methods.

Introduction
The peritoneum is an extensive serous membrane covering the entire
abdominal wall of the body and the free surfaces of internal organs. It consists
of a single layer of mesothelial cells that normally permit the viscera to glide
easily against the abdominal wall and each other. Damage to these mesothelial
cells results in the exposure of the underlying basement membrane. Leukocytes
attracted to and stimulated by extracellular matrix components release immune
mediators, or cytokines, that can either lead to repair of the mesothelium or
trigger the overproduction of fibrous connective tissue (fibrosis). In extreme
cases, thick sheets of scar tissue can constrict, resulting in irreversible alteration
of organ structure and function. The factor(s) responsible for determining
whether re-establishment of an intact mesothelium can take place prior to the
production of excessive scar tissue is (are) unclear at present. Injury to the
mesothelium can be triggered by a variety of conditions, including
intraperitoneal immunotherapy (Steis et al. 1990; Urba et al. 1989), surgery
(Fabri and Rosemurgy 1991), peritoneal dialysis (Daugirdas et al. 1986; Gandhi
et al. 1980), or tumor cell growth (Frieman, Muller, and Pott 1990; Vlasveld et al.
1992).
These effects are likely due to the elaboration of mediators secreted by
both resident peritoneal cells (primarily macrophages) and infiltrating
inflammatory leukocytes in response to local activation. These mediators,
including platelet-derived growth factor (PDGF) and transforming growth
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factor-P (TGF-p), stimulate the proliferation of fibroblasts and the deposition of
collagen (for a review, see Kovacs 1991), resulting in the permanent alteration of
the peritoneal architecture. We have previously shown that supernatants from
interleukin-2 (IL-2) stimulated leukocytes induce the proliferation of fibroblasts
(Kovacs and Neuman 1991).
There is no established method for the assessment of peritoneal
connective tissue deposition. Current methods for quantification of a fibrotic
response are crude, at best. Thus, our aim was to develop a method by which
peritoneal response to inflammatory stimuli could be critically evaluated. Talc
(hydrous magnesium silicate) was used to initiate an inflammatory event, since
this agent has long been known to cause adhesion formation (Eismann, Seelig,
and Womack 1947; Lichtman et al. 1946). We examined several parameters as
potential indicators of fibrosis. These included: (1) a gross visual inspection
and scoring of the peritoneal cavity for adhesion formation; (2) a measurement
of the connective tissue thickness between the abdominal wall muscle and
mesothelium; and (3) a determination of the cell populations present in the
abdominal cavity during this process.

The resulting data show that

measurement of connective tissue thickness gave the most accurate assessment
of connective tissue deposition in comparison to the other methods.

Materials and Methods

Reagents
Talc (hydrous magnesium silicate, H203Si3 / 4Mg1) was obtained from
Sigma Chemical Co. (St. Louis, MO). Phosphate-buffered saline (PBS) was
obtained from Gibco Laboratories (Grand Island, NY).
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Animals
Female C57BL/ 6 mice, 8-10 weeks of age, were obtained from Harlan
Laboratories (Indianapolis, IN).

Animals were maintained on a 12 hour

light/ dark cycle and provided with food and water ad libidum.

All

experimental procedures were performed in accordance with Loyola University
Animal Research Facility guidelines.

Induction of Peritoneal Adhesions
Suspensions of talc in PBS (20, 30, 50, or 100 mg of talc per 1 ml of PBS) or
PBS alone were injected intraperitoneally into mice. After 14 days, animals
were sacrificed for analysis of peritoneal abnormalities.

Collection and Analysis of Peritoneal Cells
To assess the abdominal cell population, peritoneal lavage was
performed by instilling 5 ml of chilled calcium/magnesium-free PBS into the
peritoneal cavity. The peritoneal cavity was carefully opened and the fluid
withdrawn. The lavage fluid was centrifuged at 1000 X g for 10 minutes and the
resulting cell pellet resuspended in RPMI 1640 with 10% fetal bovine serum at a
concentration of 500,000 cells/ml.

200 ml of this suspension was

cytocentrifuged for 10 minutes at 550 rpm. Slides were removed, allowed to air
dry and then fixed in methanol for 10 minutes. The cells were stained with
Modified Wright Giemsa stain (Sigma) for differential analysis. A total of 300
cells were counted per animal.
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Analysis of Peritoneal Cavity and Adhesion
Scoring
The peritoneal cavity was opened and the number of adhesions assessed
according to a scale developed by Myllarniemi et al. (Myllarniemi et al. 1966) A
score of 1 indicated no adhesions, 2 indicated one to three separate adhesions, 3
indicated three or more distinctly separate adhesions and 4 indicated diffuse,
sheet-like adhesions.

Histological Analysis of Peritoneal Wall Connective
Tissue Deposition
The right upper quadrant of the abdominal wall was removed and
placed in 10% buffered formalin. Formalin-fixed tissue was dehydrated in
varying grades of ethanol and xylene and embedded in paraffin.

Tissue

sections were cut at 4 mm and stained for connective tissue components using
Masson's Trichrome stain (Luna 1968). This procedure differentially stains
connective tissue elements, such as collagen and muscle tissue, blue and red,
respectively. Sections were deparaffinized and hydrated to distilled after, after
which they were mordanted in Bouin's solution for one hour at 560C, cooled
and rinsed in distilled water. This was followed by staining with Biebrich
scarlet-acid fuchsin solution for 2 minutes and a rinse in distilled water.
Sections were next placed in a phosphomolybdic-phosphotungstic acid solution
for 10 minutes and rinsed in distilled water. After staining in aniline blue
solution for one minute and a subsequent rinse in distilled water, slides were
placed in glacial acetic acid for one minute.

Finally, slides were rinsed,

dehydrated through a series of alcohol gradations, cleared in xylene and
mounted with Accu-Mount (Baxter Healthcare Products; McGaw Park, IL).
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Sections were examined by light microscopy and the thickness of the connective
tissue between the fragmented mesothelium and the abdominal muscle
measured in mm. Each tissue sections was measured at ten random locations;
five tissue sections were examined per animal. Each treatment group consisted
of 5-7 animals. Measurements of trichrome stained connective tissue excluded
spaces which were occasionally present and are presumably a result of
sectioning artifacts.

Statistical Analysis
Data are expressed as mean + SEM where appropriate.

Data on

peritoneal membrane thickness were compared using a one-way ANOV A
followed by Tukey's honestly significant difference.

Results

Adhesion Scores of Mice Treated with Various
Concentrations of Talc
All of the animals receiving an intraperitoneal injection of talc developed
some form of adhesions. Table I shows the adhesion score rating for the
different treatment groups. Control mice did not develop adhesions, whereas
animals receiving the highest dose (100 mg of talc) had diffuse continuous
adhesions. Mid-range doses yielded intermediate levels of adhesions. While
this scoring method gave a quick analysis of the fibrotic response, it did not
permit the assessment of subtle differences, especially between the midrange
treatment groups.
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TABLE I: Peritoneal Adhesion Scores in Talc-Treated Mice

TREATMENT
Saline
20 mg Talc
30 mg Talc
50 mg Talc
100 mg Talc

1
2
3
3
4

aMice received a single intraperitoneal injection of varying doses of talc (n = 7).
were scored by gross visual inspection fo the peritoneal cavity. A
score of 1 = no adhesions; 2 = 1 to 3 separate adhesions; 3 = some (3 or more
separate) adhesions; 4 =abundant, diffuse, or sheet-like adhesions.

b Adhesions

Quantitative Assessment of Connective Tissue
Deposition on the Abdominal Wall
Figure 6 shows photomicrographs of representative sections taken from
animals 14 days after receiving a single intraperitoneal injection of talc. Upon
histologic examination, an increase in connective tissue was noted in animals
receiving the upper talc dosages. This increase appeared as a thickening
between the abdominal wall surface (striated muscle) and the fragmented
mesothelial layer of the peritoneum. Connective tissue deposition was not
observed in animals treated with saline alone.
Measurement of trichrome stained sections revealed that there was a
dose-dependent increase in abdominal wall connective tissue thickness. Figure
7 shows a comparison of the treatment groups and their respective thicknesses.
The 50 and 100 mg talc treatment groups differed significantly from the saline
control animals (p<0.0001). Although the 30 mg talc treatment group did not
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significantly differ from the saline control animals in the statistical analysis
there was a definite trend noted between this group and the saline controls.
Thus, these measurements revealed quantitative differences between groups
that were not apparent using crude adhesion scores alone.

Peritoneal Cell Populations
While connective tissue thickness was markedly altered in talc-treated
animals, resident peritoneal cell populations did not change in comparison to
control animals. Figure 8 shows the percentage of macrophages, lymphocytes,
and polymorphonuclear cells (PMNs) present in the lavage fluid of each
treatment group with the macrophage population accounting for the majority of
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Figure 6. Thickness of Connective Tissue on Peritoneal Surface of Abdominal
Muscle 14 Days After Treatment with Talc. Shown are representative sections
of trichrome-stained abdominal wall with increasing amounts of connective
tissue between the musculature and the fragmented peritoneal mesothelium. a
is from an animal treated with saline alone; bis from an animal that received 20
mg of talc; c: 30 mg of talc; d: 50 mg of talc; and e: 100 mg of talc (magnification
SOOX).

40

140

*

~

6
::l

...._,,

120

rJJ
rJJ

100

z~

80

~

60

µ;J

u
:I:
~

40

<
µ;J

20

~

0

z

0

20

30

50

100

n=7

n=6

n=S

n=6

n=S

TALC DOSE (mg)
Figure 7. Peritoneal Wall Connective Tissue Thickness 14 Days After
Treatment. Thickness, in mm, was assessed using Masson's Trichrome stain
(see Materials and Methods section). Doses of 50 and 100 mg talc were
significantly different (p<0.001) from saline treated animals.

cells in the peritoneal cavity. Initial attempts were made to analyze the total
number of PEC in all treatment groups. Because the adhesions literally walled
off areas in the peritoneal cavity, collection of PEC was difficult. This rendered
quantitative assessment of the total number of cells impossible.
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Figure 8. Differential Cell Count of Peritoneal Cells 14 Days After Treatment.
No significant difference was observed between treatment groups.

Discussion
The intraperitoneal injection of talc resulted in a fibrotic response,
causing both the development of peritoneal adhesions (Table I) and an increase
in connective tissue deposition at the border between the peritoneal
mesothelium and the intraabdominal wall (Figure 6). We observed an increase
in the amount of connective tissue elements, including extracellular matrix and
mesenchymal cells, within the submesothelial space, in accordance with
previous studies (Renvall, Lehto, and Penttinen 1987). This reaction appeared
to be dose-dependent, with the higher doses of talc (50 and 100 mg) causing a
significantly greater thickness of connective tissue than saline alone (p<0.001).
The use of connective tissue thickness measurements to assess the fibrotic
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response gave a much more quantitative analysis of the degree of connective
tissue deposition in the peritoneal cavity than the adhesion score method of
Myllarniemi et al. (Myllarniemi et al. 1966) or than analysis of PEC composition
(Figure 8).
In animals, the cells in the peritoneal fluid normally consist of 25-70%
macrophages (Casciato, Goldberg, and Bluestone 1976). We found this to be
true for our saline control animals. However, at 14 days after talc treatment,
animals did not show any changes in peritoneal cell composition. This suggests
that, while the differential population of resident cells remained the same, the
production of fibrogenic cytokines by those cells may be altered. Since the
macrophage population constitutes the majority of cells within the peritoneal
cavity and macrophages are intimately involved in wound healing/tissue
remodeling (Leibovich and Ross 1975), it is likely that resident peritoneal
macrophages are responsible for the elaboration of fibrogenic cytokines in the
study described herein.
It was our purpose to develop a more accurate method of assessing the

fibrotic response within the peritoneal cavity. Peritoneal fibrosis is a frequent
complication in both disease states and therapy regimens and yet there is no
standard method of assessing the degree of adhesions. Until now, grading
scales were the only means of rating connective tissue deposition. While these
types of ratings are helpful, they do not delineate the more subtle differences.
Our method provides for more distinction between treatment groups. In
addition, this method has applications for in vivo assessment of topically
applied therapeutic materials, such as Interceed (TC-7, oxidized regenerated
cellulose; Diamond et al. 1991; Linsky et al. 1987)) a surgical adjuvant that was
developed for prevention of adhesion formation. An animal could be treated
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with Interceed (or other potential antifibrotic agents) on one side of the
peritoneal cavity with the other side serving as an internal control, allowing for
a quantitative in vivo evaluation of the tissue repair process.

CHAPTER4
ESTROGEN REGULATION OF ABDOMINAL CONNECTIVE
TISSUE DEPOSITION

Abstract
Estrogen's involvement in inflammation and wound healing is poorly
understood. To examine the role of estrogen in peritoneal adhesion formation,
we gave ovariectomized female C57BL/ 6 mice time-release pellets containing
placebo, 0.05 mg 17f3-estradiol (low E2 ), or 5 mg

17~-estradiol

(high E2 ) before

i.p. injection of talc in saline or saline alone. Analyses of abdominal wall
connective tissue thickness and peritoneal cell populations were performed.
Talc-treated mice receiving low and high E2 replacement had a decreased
amount of abdominal connective tissue deposition (29% and 65% decrease,
respectively) as compared with talc-treated mice receiving placebo pellets. At
high E2 replacement, the difference in connective tissue deposition was
significantly statistically (p< 0.01). Immunohistochemical analysis revealed that
the number of macrophages in adhesion tissue was proportionate to the amount
of connective tissue present, regardless of the circulating levels of E2 • Northern
blot analysis of abdominal wall tissue showed that five of six talc-treated
animals given placebo expressed mRNA for the murine monocyte
chemoattractant protein-1 (MCP-1), JE. Conversely, only one of five talc-treated
animals that received E 2 replacement expressed JE/MCP-1 mRNA, suggesting
that the hormone may inhibit connective tissue deposition by altering the
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production of chemotactic factors. Furthermore, E 2 suppressed talc-induced
expression of JE/MCP-1 mRNA in murine macrophages. Since macrophages
play a central role in the wound healing process, these studies suggest that E2
inhibition of adhesion formation could be mediated by suppressing
macrophage activation and/ or recruitment to inflammatory sites.

Introduction
The sexual dimorphism of the immune response is well-documented
(Ansar-Ahmed, Penhale, and Talal 1985; Grossman 1985; Schuurs and Verhuel
1990), yet the role the sex steroid hormone, estrogen, plays in the regulation of
immune cell functions is only beginning to be understood. Connective tissue
disorders and autoimmune diseases, such as scleroderma, lupus erythematosus,
and rheumatoid arthritis are more prevalent in women of reproductive age than
in women of all ages as well as in men and the severity of these disease states is
often altered during pregnancy (Czirjak et al. 1989; Holmdahl and Jansson 1988;
Steen 1990; Steen and Medsger 1990) . Elevated levels of circulating estrogen
prevent certain pathologic conditions and can even trigger reversal of disorders.
This is best demonstrated in post-menopausal women receiving estrogen
replacement therapy, where hormonal replacement prevents bone loss
(Christiansen 1993) and reduces the risk of coronary artery disease (Knopp
1988). These conditions are mediated by local activation of inflammatory and
immune cells. Since these immune cell populations, including monocytes,
macrophages, lymphocytes, and mast cells, express estrogen receptors
(Cocchiara et al. 1990; Gulshan, McCruden, and Stimson 1990; Weusten et al.
1986), it suggests that the hormone could directly affect functions of these cells,
including cytokine production.
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Fibrosis, or adhesion formation in the abdomen, is an end phase in the
inflammatory response that can cause a multitude of disorders such as bowel
obstruction (Krebs and Goplerud 1987) and infertility (Haney 1993). As in other
systems, the deposition of abdominal connective tissue involves a cascade of
events. Macrophages are recruited into the site of injury, where they secrete a
host of mediators that in turn trigger the proliferation of fibroblasts and the
synthesis and secretion of extracellular matrix proteins, such as collagen (for
reviews see (Kovacs 1991; Kovacs and Pietro 1994)). It is well established that
glucocorticoids have an inhibitory effect on the wound healing process by
suppressing collagen synthesis (Cockayne et al. 1986; Cutroneo, K.M. Sterling,
and Schull 1986; Walsh, LeLeiko, and K.M. Sterling 1987) and cytokine
production (Beutler et al. 1986; Kawahara, Deng, and Deuel 1991; Lee et al. 1988;
Mukaida et al. 1991; Snyder and Unanue 1982; Staruch and Wood 1985; Waage,
Slupphaug, and Shalaby 1990).

However, the effects of gonadal steroid

hormones on connective tissue deposition and the wound healing process have
yet to be examined.
Since estrogen modulates inflammatory responses in other systems, we
hypothesized that it could alter the deposition of connective tissue in an in vivo
model of peritoneal adhesion formation (Frazier-Jessen and Kovacs 1993), in
which a suspension of talc was administered intraperitoneally. Talc from
surgical gloves has been shown to cause adhesions following abdominal
surgery (Henderson et al. 1978; Kus et al. 1979; Sheikh et al. 1984) and serves a
reliable stimulus to trigger adhesion formation (Frazier-Jessen and Kovacs
1993). In this report, we show that estrogen suppresses connective tissue
deposition in a dose-dependent manner and that this might be mediated
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through inhibition of migration of resident peritoneal macrophages into the
damaged tissue site by E2 •

Materials and Methods

Reagents
Talc (hydrous magnesium silicate, H 20 3Si314Mg 1 ),

17-~-estradiol

(E 2),

hydrogen peroxide, and diaminobenzidine tablets were obtained from Sigma
Chemical Co. (St. Louis, MO). Brewer's thioglycolate and LPS were obtained
from DIFCO (Detroit, MI). The F4/80 rat monoclonal antibody was a kind gift
from Dr. Gary Wood (University of Kansas; Kansas City, KS). Normal donkey
serum, biotinylated donkey anti-rat IgG, and purified rat IgG were obtained
from Jackson ImmunoResearch Laboratories, Inc. (West Grove, PA).

The

Vectastain Elite ABC immuno-peroxidase kit was obtained from Vector
Laboratories, Inc. (Burlingame, CA).

17~-estradiol

(E 2 ) time-release pellets and

placebo pellets were obtained from Innovative Research of America (Toledo,
OH). The E 2 pellets were designed to release a total of 0.05 mg (low) or 5 mg
(high) of E2 over 21 days. All tissue culture reagents and random primer
labeling kit were obtained from Gibco/BRL (Grand Island, NY).

Ovariectomy and E2 Replacement
Female C57BL/6 mice, 8 to 10 weeks of age, were obtained from Jackson
Laboratories (Bar Harbor, ME). All experimental procedures were performed in
accordance with Loyola University Animal Research Facility guidelines.
Ovariectomy (OVX) was performed to eliminate the major source of
endogenous estrogens. Immediately following surgery, 21-day

time~release
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pellets containing either 0.05 or 5.0 mg of E2 (the most biologically active form
of estrogen), or vehicle alone, were implanted subcutaneously on the back
according to manufacturer's directions. These concentrations of E2 were chosen
to deliver low physiologic levels (20 to 30 pg/ml; low E 2 ) and high pregnancy
levels (2000 to 3000 pg/ml; high E 2 ), respectively, as described by the
manufacturer (Bain et al. 1993; Langdon et al. 1993). In mice, the upper limit of
normal for ciculating preovulatory E2 levels is 200 to 300 pg/ml.
Animals were allowed to recover from surgery for 7 days before the
induction of peritoneal adhesion formation. This time point allowed steroid
hormone levels to equlibrate, which, according to the manufacturer, occurs
within 48 hours of pellet implantation, and permitted complete healing of the
peritoneal mesothelial lining, which takes less than 1 week (Ellis, Harrison, and
Hugh 1965; Hubbard et al. 1967). The latter point is of importance to the study,
because we wanted to insure that the surgical intervention into the abdominal
cavity (required for OVX) did not interfere with pertioneal adhesion formation.

Induction of Adhesion Formation
Adhesion formation was induced by a single i.p. injection of a
suspension of 30 mg of talc in saline (or saline alone as a control), as previously
described (Frazier-Jessen and Kovacs 1993). Fourteen days after talc or saline
injection, animals were killed for collection of resident peritoneal cells, tissue
smaples of abdominal wall, and uteri.

Uterine weight measured at the

completion of the study was used as an indication of systemic estrogen
delivery.
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Collection and Analysis of Peritoneal Cells
To assess changes in peritoneal cell populations following E2 and talc
treatment, peritoneal lavage was performed as previously described (FrazierJessen and Kovacs 1993). Peritoneal cells were collected by cytocentrifugation,
fixed in methanol, and stained with Modified Wright Giemsa stain for
differential analysis. A minimum of 300 cells was counted per animal.

Histological Analysis of Peritoneal Wall Connective
Tissue Deposition
The right upper quadrant of the abdominal wall was removed and
placed in 10% buffered formalin, sectioned, and stained for connective tissue
components using Masson' s Trichrome stain as previously described (FrazierJessen and Kovacs 1993). Thickness of the connective tissue between the
fragmented mesothelium and the abdominal muscle was measured in microns.
Each 4-µm tissue section was measured at 10 random locations; five tissue serial
sections were examined per animal.

Measurements of trichrome-stained

connective tissue excluded spaces that were occasionally present and are
presumed to result from sectioning artifacts.

Immunohistochemical Analysis of Macrophages in
Abdominal Wall Adhesion Tissue
The left upper quadrant of the abdominal wall was placed in O.C.T.
compound (Miles Laboratories, Elkhart, IN), flash-frozen and stored at -70°C.
Six micron sections were fixed in 4% paraformaldehyde and incubated with
50% normal donkey serum for 30 minutes to reduce nonspecific staining. The
sections were then incubated sequentially with the monoclonal rat anti-mouse
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macrophage antibody, F4/80, or with purified rat IgG (as a control antibody)
for 1 hour and then with biotinylated donkey anti-rat IgG for 30 minutes.
Endogenous peroxidase activity was blocked by exposure to 0.3% hydrogen
peroxide before incubation with Vectastain Elite ABC immunoperoxidase kit.
Horseradish peroxidase enzyme activity was detected by immersing the slides
in 0.45 mg/ml diaminobenzidine (DAB) in buffer containing 0.15M NaCl, 0.05M
Tris, and 0.07% H 2 0

2.

Sections were counterstained in methyl green and

observed by bright field microscopy. The number of positive staining cells per
given area was counted, using National Institutes of Health Image Analysis
software, and expressed as number of cells/µm 2 . Five areas per section were
measured, with two sections for placebo/talc-treated animals, and three for
high E2 /talc-treated animals. Because of the limited amount of connective
tissue in saline-treated mice, assessment of immunoreactive cells was not
performed on those animals.

Isolation and Culture of Thioglycolate-Elicited
Murine Peritoneal Macrophages
Cycling female C57BL/ 6 mice were injected i.p. with 1.5 ml of 10%
Brewer's thioglycolate (Difeo), as previously described (Radzioch, Bottazzi, and
Varesio 1987). Four days later, animals were killed and peritoneal lavage was
performed, and cells were plated at 2 X 10 6 cells/ml of phenol red-free RPMI
1640 medium with 2% fetal bovine serum, 100 U/ml penicillin, 100 mg/ml
streptomycin, and 2mM L-glutamine, as previously described (Frazier-Jessen
and Kovacs 1995). Two hours after plating, medium containing nonadherent
cells was removed and replaced with fresh medium. The remaining cells were
>95% macrophages, as determined by Giemsa stain analysis. Macrophage
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cultures were rested for 48 hours before stimulation to diminish expression of
cytokine genes triggered by adherence to tissue culture plastic (Fuhlbrigge et al.
1987).
After resting, macrophages were cultured in the presence or absence of a
talc suspension in PBS with or without E2 for 8 hours, unlesss otherwise
specified. The concentrations of E2 (3-3000 pg/ml) were comparable with
normal circulating levels in female mice and those attained in in vivo
experiments using OVX animals given E 2 replacement. Stock solutions of E2
were prepared in ethanol.

Since ethanol is known to alter membrane

permeability that may affect activation of second messenger pathways, care was
taken to insure that effects of the steroid hormone were due to the hormone
itself, rather than the solvent. In all experiments, final concentrations of ethanol
did not exceed 0.0006%.
Parallel studies were performed using the ANA-1 murine macrophage
cell line (obtained from Dr. Luigi Varesio, Frederick Cancer Research and
Development Center, National Cancer Institute, Frederick, MD). Forty eight
hours before stimulation, ANA-1 macropahges were plated at 5 X 10 5 cells/ml
in phenol red-free RPMI 1640 medium with 2% fetal bovine serum in the
absence of exogenous stimulants, as previously described (Frazier-Jessen and
Kovacs 1995). Cells were harvested for RNA isolation after 8 h of incubation,
unless otherwise specified.

RNA Isolation and Northern Blot Analysis
Total RNA from homogenized abdominal wall tissue was isolated by a
single-step guanidinium thiocyanate-phenol-chloroform method (RNAzol B;
Cinna Biotex, Houston, TX) according to manufacturer's specifications.
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Northern blots, prepared as previously described (Kovacs, Oppenheim, and
32

Young 1986), were hybridized with P-labeled cDNA probes for murine JE
(obtained from the American Type Culture Collection, Rockville, MD) and
glyceraldehyde-3-phospate dehydrogenase (G3PDH; from Dr. Hans-Martin
Jack, Loyola University Chicago, Maywood, IL) using a random primer kit.
Eithidium bromide staining of agarose gels was performed to demonstrate even
loading of samples. Quantitation of RNA signals was performed by scanning
densitometry using Ambis Quantprobe Software version 3.02 (Ambis Systems,
Inc., San Diego, CA).

Statistical Analyses
Data are expressed as mean ± SEM. Data on uterine weight, peritoneal
membrane thickness, and cell populations were compared using a two-way
analysis of variance.

A p value < 0.05 was considered to be significant

statistcally. Studies were performed with a minimum of six animals per group,
unless otherwise stated.

Results

Uterine Weight of Ovariectomized Animals With
or Without E 2 Replacement
Uterine weight has previously been reported to serve as an accurate
assessment of systemic estrogen exposure in OVX mice (Butterstein, Damassa,
and Sawyer 1980; Gee et al. 1984; Mobbs et al. 1985).

In the absence of

circulating estrogen (OVX with placebo pellets), uterine weight is low, as shown
in Table IL These values are comparable with the reduced uterine weight
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observed in 6 week old C57BL/6 mice that averaged 19 ± 0.8 mg 2 weeks after
OVX (Jesionowska, Karelus, and Nelson 1990). Physiologic replacement of E2 in
OVX animals results in a three- to fourfold increase in uterine weight over OVX
animals that do not receive E 2 replacement (p < 0.01). These uterine weights in
Ertreated mice were higher than the levels reported for uterine weight in 6
week old C57BL/ 6 mice that ranged from a low of 52 ± 3.3 mg during
midestrus to a high of 88 ± 8.5 during proestrus (Jesionowska, Karelus, and
Nelson 1990). However, they are consistent with other studies performed in
C57BL/ 6 (Gee et al. 1984; Mobbs et al. 1985) and other strains of mice (De and
Wood 1990). In addition, high E 2 replacement stimulates a significant increase
in uterine weight, but to a lesser extent than low physiologic E2

TABLE II: Uterine Weight of Ovariectomized Mice Given E2 Replacement With
or Without i.p. Talc Administration

Uterine Weight (mg)b

fu Statusa
placebo
lowE 2
high E2

Saline
35.75 ± 8.25 (n=4)
145.33 ± 5.81 (n=3)*
113.6 ±_9.56 (n=3)*

Talc
39.33 ± 10.28 (n=6)
111.00 ± 7.77 (n=5)*
89.86 ± 3.40 (n=7)*

Data are shown as mean + SEM.
3

Mice were ovariectomized and implanted with pellets that released a total of
0.05 mg E2 (low E2), 5 mg E2 (high E2 ) or vehicle (placebo) over a 21-day period.
bMice were injected i.p. with talc (30 mg in 1 ml saline) or saline 7 days postovariectomy /E 2 replacement. Fourteen days later, uteri were dissected out and
weighed for verification that E2 doses were within reported appropriate ranges.
*p < 0.01 from placebo-treated animals.

54
replacement (p < 0.01), which has been reported previously by others (Bergman
et al. 1992; Jesionowska, Karelus, and Nelson 1990). This difference is attributed
to suppression of cycling frequency in mice given high E2 levels relative to those
treated with lower levels of the hormone, as previously reported (Bain et al.
1993; Langdon et al. 1993). Finally, we also observed that the uterine weights
from talc-treated OVX animals given E2 replacement were less than the weight
of uteri in saline-treated mice, as there is no difference in the body weight of the
animals in the treatment groups. It may be attributed to the presence of
adhesions on the uteri of the talc-treated mice that restricted the aqueous weight
gain of the organ; however, histologic analysis of the uteri would need to be
performed to confirm this.

Assessment of Connective Tissue Deposition in the
Abdominal Cavity
Data from representative trichrome-stained abdominal wall sections
obtained from mice injected with either talc or saline are shown in Figure 9.
Normally, the peritoneum consists of a single layer of mesothelial cells and their
underlying basement membrane (Figure 9a). Animals injected with saline alone
did not develop peritoneal membrane thickening, regardless of E2 replacement.
Injection of talc causes disruption of the peritoneal mesothelium and thickening
of the underlying connective tissue (Figure 9b ). This connective tissue consists
primarily of inflammatory cells, fibroblasts, and collagen. Less connective was
observed in talc-treated animals given low and high E2 replacement (Figure 9, c
and d, respectively) than talc-treated mice given placebo. Our quantitative
assessment of peritoneal connective tissue thickness revealed that, in
OVX/placebo mice, talc treatment triggered a fourfold increase in peritoneal
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membrane thickening as compared with saline-treated controls (p < 0.01; Figure
10). Peritoneal connective tissue deposition in talc-treated animals receiving
low E2 replacement and high E2 replacement was diminished markedly (29%
and 65%, respectively) when compared with talc-treated mice given placebo
pellets. At high physiologic E2 replacement, this decrease in connective tissue
accumulation was signficant statistically (p < 0.01).
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Figure 10. Effect of E 2 Replacement on Peritoneal Connective Tissue Thickness
in Ovariectomized Mice Receiving Intraperitoneal Injection of Talc (30 mg) in
Saline. Thickness, in microns, was assessed by light microscopy of Masson's
Trichrome stained abdominal wall tissue (see Materials and Methods). Data
shown are means± SEM. *p<0.01 from PBS-treated controls. #p<0.01 from talctreated placebo control.
Peritoneal Cell Populations
To determine whether administration of talc and/ or E 2 treatment caused
alterations in the resident peritoneal cell populations, absolute and differential
counts of peritoneal lavage cells were performed. Attempts were made to
analyze the total lavage cell numbers in all treatment groups. Because of the
severity of adhesions in the talc-treated animals, quantitative recovery of
peritoneal cells was difficult, as previously described (Frazier-Jessen and
Kovacs 1993).
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TABLE III: Resident Peritoneal Cell Populations

Treatment Groupa

%Neu trophilsb

%Macrophages b

%Lymphocytesb

placebo I saline
placebo I talc
low E2 / saline
low E2 /talc
high E2 / saline
high E2 I talc

8.33 ±3.45
19.13 ± 3.85*
9.75 ±3.75
25.10 ± 5.03*
10.33±1.33
20.60 ± 1.83**

69.60 ±3.25
46.53 ± 3.63*
67.05 ± 7.85
58.56 ±6.19
66.03 ±5.29
53.03±6.34

21.75 ± 4.99
34.32 ± 6.25
21.95 ± 4.35
16.36±1.63
23.43 ± 4.42
26.37 ±5.48

aMice were ovariectomized and implanted with pellets that released a total of
0.05 mg E 2 (low E2), 5 mg E2 (high E2), or vehicle (placebo) over a 21-day period.
Seven days post-ovariectomy /E 2 replacement, mice were injected i.p. with talc
(30 mg in saline) or saline alone. Fourteen days later, animals were sacrificed
and peritoneal lavage was performed. Resident peritoneal cell populations
were differentially assessed by Wright's Modified Giemsa stain (see Materials
and Methods).
bData are expressed as mean+ SEM.
*p < 0.01 between saline- and talc-treated animals of each E2 group.
**p < 0.03 between saline- and talc-treated animals of each E2 group.

It is likely that the poor and inconsistent cell recovery observed in the talc-

treated mice that results, in part, from sequestration of peritoneal cells at
adhesion sites.
Differential cell counts yielded the percentages of neutrophils,
macrophages, and lymphocytes in peritoneal lavage fluid (Table III). Talc
treatment caused a significant increase in the proportion of peritoneal
neutrophils over that obtained from saline-treated animals (p < 0.01).

No

difference was observed between the peritoneal cell populations in salinetreated animals given E2 or placebo pellets. There was a significant decrease in
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the peritoneal macrophage population in talc-treated placebo animals compared
with saline-treated placebo animals (p < 0.01), possibly resulting from
adhesiveness of the cells following talc administration. This was not observed
in talc-treated animals receiving either low or high E2 replacement, suggesting
that hormone treatment may decrease macrophage activation or migration in
vivo. Finally, no significant differences in peritoneal lymphocyte populations
were observed between any of the experimental groups.

Immunohistochemical Detection of Macrophages in
Adhesion Tissue
Since macrophages are believed to play a central role in inflammation
and wound repair (Leibovich and Ross 1975), we wanted to determine whether
E 2 treatment affected the number of macrophages present in the connective
tissue of talc-treated animals. Immunohistochemical analysis of abdominal wall
tissue using the F4/80 monoclonal antibody for detection of macrophages
revealed the presence of macrophages in connective tissue was observed
between placebo and high E2 treatment groups (9.9 and 8.8 cells per 100 µm 2,
respectively), even though E 2 replacement decreased connective tissue
deposition. The number of macrophages per unit area of adhesion tissue
reported herein did not differ from that of connective tissue in models of skin
wound healing (DiPietro et al. 1995; Wong et al. 1993). However, it was greater
than in the connective tissue of normal undamaged murine skin (DiPietro et al.
1995) and other organs (Kovacs, unpublished observations).
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Expression of JE/MCP-1 mRNA in Abdominal Wall
Tissue of Talc-Treated Mice
Since E2 replacement diminished peritoneal adhesion formation and we
recently reported that E2 suppresses expression of JE/MCP-1 mRNA in cultured
murine macrophages (Frazier-Jessen and Kovacs 1995), we wanted to determine
whether expression of this gene in adhesion tissue could be responsible for the
macrophage recruitment to or activation at sites of tissue damage. Northern
blot analysis revealed that JE/MCP-1 mRNA transcripts were not detected in
abdominal wall connective tissue samples obtained from four saline-treated
mice. In contrast, the message was expressed in samples from five of six talctreated OVX mice given placebo or no E2 replacement (Figure 11, lanes 4-7) and
in only one of five samples from talc-treated OVX mice given E2 replacemnt
(three of which are shown in Figure 11, lanes 8-10). In these experiments, RNA
from abdominal wall tissue from untreated animals (lane 1) and a murine
macrophage cell line, ANA-1, with LPS (1 µg/ml) (lane 2) served as negative
and positive controls, respectively. Table IV shows a densitometric analysis of
the Northern blot. In addition, we monitored the expression of other proinflammatory and fibrogenic cytokines, including IL-la,
and platelet-derived growth factor a- and

~-chains.

IL-1~,

TNF-a,

TGF-~1,

We observed that the
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Table IV: Densitometric Scan of Northern Blot of JE mRNA Expression from
Murine Abdominal Wall Tissue

Treatmenta
Untreated
ANA-1 cells+ LPS (1 µg/ml)
Talc
Talc
Talc+ Vehicle
Talc+ Vehicle
Talc
Talc+ E2
Talc+ E2
Talc+ E2

JEmRNA
ODUnitsb
0

206
3.5

5
5.1
4

4.3
0
0

0.2

a Total cellular RNA was obtained from abdominal wall tissue of C57BL/6 mice
that were ovariectomized, ovariectomized and received E2 (300 pg/ml), or
vehicle only. RNA from abdominal wall tissue of an untreated animal and
RNA from LPS-stimulated ANA-1 macrophages were used as negative and
positive controls, respectively. The blot was hybridized with 32P-labeled cDNA
probes for murine JE.
bArbitrary units obtained from scanning densitometric analysis of x-ray filters.

expression of these cytokine genes in abdominal wall tissue samples was below
the level of detection. This may have been due, in part, to the selection of late
time point examined (14 days post-talc treatment).
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Estrogen Inhibition of Talc-Induced Expression of
JE/MCP-1 mRNA in Murine Macrophages
Since peritoneal macrophages play a role in the generation of connective
tissue in the abdominal cavity in other systems, we wanted to determine
whether exposure to talc could induce JE/MCP-1 mRNA expression in vitro,
and if so, whether treatment with E2 could suppress the talc-induced expression
of the message. To accomplish this, we cultured thioglycolate-elicited murine
peritoneal macrophages in the presence or absence of talc with or without E2 .
Minimal or undetectable levels of JE/MCP-1 mRNA were expressed in
untreated macrophages.

Expression of the message could be increased

following 8 h of exposure to increasing concentrations of talc (from 0.01 to 100
µg/ml). At 100 µg/ml, this level ranged from 19- to 32-fold that of untreated
cells, which respresents one-fifth of the maximal levels of JE/MCP-1 mRNA
induced after exposure to lµg/ml LPS.

While E2 alone had no effect on

expression of the message, the addition of E2 to talc-treated macrophages
resulted in inhibition of expression of JE/MCP-1 mRNA. The concentrations of
E 2 used in these studies were at or below the circulating hormone levels
achieved by implantation of E2 pellets on OVX mice. Maximal inhibition of
JE/MCP-1 mRNA expression in response to talc (100 µg/ml) was observed at
300 pg/ml of E2 • In three separate experiments, the inhibition at this dose of E2
was 94% that of cells treated with talc alone.
Since thioglycolate-elicited peritoneal macrophages purified by
adherence contain small of numbers of contaminating cells (Radzioch, Bottazzi,
and Varesio 1987) #123], we wanted to confirm that 1) talc treatment
coulddirectly induce expression of JE/MCP-1 mRNA in the absence of other cell
types, and 2) E2 exposure could suppress expression of the message in
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Figure 12. E 2 Inhibition of JE/MCP-1 mRNA Expression in Talc-Stimulated
ANA-1 Murine Macrophages. ANA-1 cells were cultured, as described in
Materials and Methods, for 8 h in the absence of stimulants, with E2 alone (300
pg/ml), with talc alone (100 µg/ml), or a combination of talc and E 2, after which
cells were harvested for RNA extraction. Quantitative analysis of E2 inhibition
of talc-induced JE/MCP-1 mRNA expression. Data are shown as the steady
state level of JE/MCP-1 mRNA expression divided by the level of G3PDH
mRNA expression in arbitrary OD units.

pure populations of macrophages. To accomplish this, parallel studies were
performed with the ANA-1 macrophage cell line derived from a male C57BL/6
mouse.

Like thioglycolate-elicited peritoneal macrophages, the ANA-1

macrophages did not spontaneously express JE/MCP-1 mRNA, but could be
induced to express the message after exposure to talc for 8 h (Figure 12). While
E 2 alone had no effect on JE/MCP-1 mRNA expression, the addition of E2 to
talc-treated cells resulted in a dose-dependent inhibition of expression of the
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message. As with peritoneal macrophages, maximal inhibition of expression
was achieved at a concentration of 300 pg/ml of E2 and ranged from 50 to 88%.
These data show that a pure macrophage population is capable of expressing
JE/MCP-1 mRNA in response to talc treatment. Furthermore, since E2 can
inhibit the expression of the message in talc-treated macrophages from male
mice, it suggests that both male and female mice have estrogen receptors
(Frazier-Jessen and Kovacs 1995; Gulshan, McCruden, and Stimson 1990;
Weusten et al. 1986) as well as other machinery necessary to respond to
estrogen treatment.

Discussion
In this study, we show that E2 suppresses connective tissue deposition in
a murine model of peritoneal adhesion formation.

Our observations are

consistent with those of other laboratories examining dermal wound healing in
estrogen-treated ovariectomized female rats (Roth, Harman, and Lamberg
1981), and rabbits (Dyson and Joseph 1971).

In these studies, daily s.c.

administration of high doses of estradiol attenuated wound healing, as assessed
by the time of wound closure in the rodent study (Roth, Harman, and Lamberg
1981) and regenerative growth in the rabbit study (Dyson and Joseph 1971).
The effects of E2 on connective tissue deposition have several important
physiologic implications.

The loss of circulating E2 , as occurs during

menopause, may permit exacerbation of inflammatory responses. This is
substantiated by clinical observations of increased serum levels of several
inflammatory cytokines in postmenopausal women (Pacifici et al. 1990; Ralston,
Russell, and Gowen 1990). Therapeutic E2 replacement in postmenopausal
women may prevent potentially harmful inflammatory responses from
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occurring. This has already been shown to be true in treatment of osteoporosis
and in reducing the risk of atherosclerosis (Knopp 1988). In addition, women
undergoing cesarean section show a relative paucity of postsurgical i.p.
adhesion formation (Golan et al. 1991) as compared with patients undergoing
other abdominal surgeries. Furthermore, decreased symptoms (i.e., pain and
joint swelling) were noted in women with rheumatoid arthritis during
pregnancy (Hench 1938; Vandenbroucke et al. 1986). These phenomena may be
due, in part, to the presence of elevated circulating E2 levels that are achieved
during pregnancy (Carr 1990). High levels of E2 could attenuate the local
macrophage-mediated inflammatory I immune response, and thereby suppress
connective tissue deposition.
Mechanism(s) by which E2 exerts its effects on the inflammatory and
fibrotic responses has not been fully addressed. Reports have demonstrated
elevated expression of JE/MCP-1 mRNA in atherosclerotic vessels (Koch et al.
1993; Nelken et al. 1991; Takeya et al. 1993; Yu et al. 1992), fibrotic lungs
(Brieland et al. 1992; Flory, Jones, and Warren 1993), and dermal wound healing
(DiPietro et al. 1995). The correlation between the incidence of expression of
JE/MCP-1 mRNA in abdominal wall tissue and the amount of connective tissue
deposited following E2 treatment suggests that hormone may diminish
adhesion formation by blocking the recruitment or activation of macrophages.
Taken with our data on immunohistochemical localization of macrophages in
adhesion tissue, it is reasonable to suggest that the hormone may also attenuate
the production of other proinflammatory and fibrogenic cytokines that can
directly trigger fibroblast proliferation and collagen synthesis (Kovacs 1991;
Kovacs et al. 1993). This is currently being pursued in our laboratory.
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It is also possible that the effects of E2 on peritoneal adhesion formation

are mediated indirectly by estrogen stimulation of glucocorticoid production,
which has been shown to decrease or delay wound healing (Leibovich and Ross
1975), and inhibit the proliferation of fibroblasts (Ponec et al. 1977; Saarni and
Tammi 1978) and the synthesis of collagen (Cockayne et al. 1986; Walsh,
LeLeiko, and KM. Sterling 1987), the hallmarks of the fibrotic response. Such a
mechanism is also supported by the observation that glucocorticoids suppress
the expression of JE/MCP-1 mRNA (Kawahara, Deng, and Deuel 1991;
Mukaida et al. 1991). However, the fact that E2 inhibits expression of the
message in talc-treated macrophages (Figure 12) demonstrates a direct means
by which the hormone could alter cytokine gene expression. This is supported
further by studies showing E2 suppression of macrophage activation in rodent
(Frazier-Jessen and Kovacs 1995; Sato et al. 1991) and human (Polan et al. 1989;
Ralston, Russell, and Gowen 1990) systems and platelet-derived growth factorstimulated murine fibroblasts (Kovacs et al. 1996). The presence of ER in the
two main cell types involved in scar tissue formation, namely fibroblasts (Malet
et al. 1991) and macrophages (Frazier-Jessen and Kovacs 1995; Gulshan,
McCruden, and Stimson 1990; Weusten et al. 1986), further suggests that E2
could directly modulate functions of these cells.
There are several ways in which E2 could exhibit effect on the expression
of JE/MCP-1 gene. Using DNA sequence analysis, we have identified the
presence of four half-palindromic ERE motifs (Kovacs, Alberta and Stiles,
unpublished observation). In other studies, identical ERE half-palindromic
sequences have been shown to regulate the expression of estrogen-dependent
genes (Kato et al. 1992). Furthermore, the proximal promoter of the JE gene
contains a silencer element that has not yet been fully characterized (Freter et al.
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1992). The presence of this element suggests that, if the half-palindromic ERE
motifs do not function to regulate transcription, then E2 may inhibit
transcription of the JE gene by interacting with novel sequences.
Recent reports reveal that in addition to the interaction of estrogen/ER
complex with genomic ERE, the hormone can also mediate its effects by
modulating intracellular second messenger pathways as well as other genomic
elements. For example, at physiologic levels E2 stimulates the accumulation of
intracellular cAMP (Aronica, Kraus, and Katzenellenbogen 1994). Webb and
colleagues (Webb et al. 1995) showed that estrogen/ER complexes may also act
by altering the ability of the c-jun protein to interact with c-fos to form the AP-1
transcription factor that binds to AP-1 sites in the promoter of rat (Timmers et
al. 1990) and murine (Kovacs and Mott, unpublished observations) JE/MCP-1
genes. This is currently being investigated in the laboratory.
In summary, we have shown that E2 attenuates connective tissue
deposition in a model of peritoneal adhesion formation, and that this inhibition
may be mediated through inhibition of macrophage activation at sites of tissue
damage.

CHAPTERS

ESTROGEN MODULATION OF JE GENE EXPRESSION IN MURINE
MACROPHAGES

Abstract
The chemotactic cytokine, monocyte chemoattractant protein-1 (MCP-1),
and its murine homologue, JE, have been detected in atherosclerotic lesions but
not in normal arteries, implicating that these pro-inflammatory cytokines may
be involved in the pathogenesis of atherosclerosis. Epidemiologic studies reveal
that postmenopausal women receiving estrogen replacement for treatment of
osteoporosis have a greatly reduced risk of developing cardiovascular disease.
Because JE/MCP-1 and estrogen play regulatory roles in the development of
atherosclerotic lesions, we chose to examine the effects of estrogen treatment on
JE/MCP-1 mRNA expression in macrophages.

17~-estradiol

(E 2) inhibited LPS-

stimulated JE/MCP-1 mRNA expression in ANA-1 and J774A.1 murine
macrophage cell lines and in thioglycolate-elicited murine peritoneal
macrophages. Inhibition of JE/MCP-1 mRNA ranged from 50 to 90%, with a
maximal effect occurring at a concentration of 300 pg/ml E 2 • Conversely, E2
had little effect on LPS-stimulated TNF-a mRNA production. Treatment of
LPS-stimulated macrophages with moxestrol, an estrogen agonist, resulted in a
similar inhibition, and the addition of the estrogen antagonist, tamoxifen,
reversed E 2 inhibition of LPS-induced JE/MCP-1 mRNA expression.
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Immunohistochemical analysis revealed the presence of estrogen receptors in
ANA-1 cells, indicating that E2 inhibition of LPS-induced JE/MCP-1 mRNA
expression in murine macrophages may be mediated through the estrogen
receptor. Thus, another mechanism whereby estrogen exerts anti-atherogenic
effects may be through prevention of macrophage accumulation in the
atherosclerotic lesion.

Introduction
Atherosclerosis is the predominant cardiovascular disease in the United
States associated with a high mortality rate. Characteristics of the pathology of
this disease include the formation of fatty, fibrous plaques within the arterial
wall, accompanied by an inflammatory response that ultimately results in a
partial to complete occlusion of the blood vessel. The earliest recognizable
lesion in the progression of this disease is the "fatty streak" consisting, in part,
of an aggregation of lipid-laden macrophages (foam cells) within the intimal
wall of the artery. The recruitment of these macrophages to the lesion is
believed to be mediated by chemotactic cytokines (for a review, see (Ross 1993)),
such as monocyte chemoattractant protein-1 (MCP-1) (Yoshimura and Leonard
1990), which is chemotactic for mononuclear phagocytes both in vitro (Rollins,
Walz, and Baggiolini 1991; Yoshimura and Leonard 1990; Yoshizuka et al. 1989)
and in vivo (Zachariae et al. 1990). MCP-1 and its murine homologue, JE
(Yoshimura and Leonard 1990), which was identified initially as a plateletderived growth factor-inducible gene (Cochran, Reffel, and Stiles 1983), have
been detected in atherosclerotic lesions but not in normal arteries (Koch et al.
1993; Nelken et al. 1991; Takeya et al. 1993; Yu et al. 1992), suggesting that they
may play a role in the pathogenesis of atherosclerosis. Because JE/MCP-1
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production can influence macrophage recruitment to sites of injury and
inflammation, its regulation has clinical relevance for the treatment and
prevention of atherosclerosis.
One of the factors associated with an increased risk of the development
of cardiovascular disease in women is the onset of menopause (Eaker and
W.P.Castelli 1987).

Epidemiologic studies revealed that postmenopausal

women receiving estrogen replacement therapy for treatment of osteoporosis
have a reduced risk of developing cardiovascular disease (Eaker and
W.P.Castelli 1987; Henderson, Paganini-Hill, and Ross 1991; Knopp 1988;
Stampfer et al. 1991). This is caused, in part, by the effects of estrogen on low
density lipoprotein metabolism (Sacks and Walsh 1990; Schaefer et al. 1983;
Walsh et al. 1991). However, these effects alone cannot completely explain the
anti-atherogenic effects of estrogen.
Recent studies have shown that estrogen receptors are present in the
immune and mesenchymal cell populations involved in both inflammation and
atherogenesis (Sacks and Walsh 1990; Schaefer et al. 1983; Walsh et al. 1991).
This suggests that estrogen may modulate the inflammatory response by
directly affecting the expression of cytokine genes in immune cells.
Glucocorticoids have been shown to be anti-inflammatory in numerous
systems, and the synthetic glucocorticoid, dexamethasone, inhibits JE/MCP-1
mRNA expression in both fibroblasts (Kawahara, Deng, and Deuel 1991) and
macrophages (Mukaida et al. 1991; Poon et al. 1991). Other investigators have
shown that the production of IL-1 (Pacifici et al. 1990) and TNF-a (Ralston,
Russell, and Gowen 1990) can be altered by estrogen replacement therapy.
However, direct effects of estrogen on JE/MCP-1 mRNA expression have not
been examined. Because both JE/MCP-1 and estrogen may play regulatory
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roles in the pathogenesis of atherosclerosis, we chose to examine whether
estrogen treatment affects JE/MCP-1 mRNA expression in the macrophage.
Herein we show that the estrogen, E 2, can inhibit LPS-stimulated JE/MCP-1
mRNA expression in murine peritoneal macrophages and macrophage cell
lines.
Materials and Methods

Reagents
17-15-estradiol (E 2 ), progesterone, tamoxifen, hydrogen peroxide, and
diaminobenzidine tablets were purchased from Sigma Chemical Co. (St. Louis,
MO). Moxestrol was a kind gift from Rousell Uclaf (Romainville, France).
Brewer's thioglycolate and LPS were obtained from DIFCO (Detroit, Ml). All
tissue culture reagents and random primer labeling kit were obtained from
Gibco/BRL (Grand Island, NY). The cDNA probes for murine JE and murine
TNF-a were obtained from the ATCC (Rockville, MD) and Chiron Corporation
(Emeryville, CA), respectively. The ER-21 rabbit polyclonal antibody against
estrogen receptor was a generous gift of Dr. Geoffrey Greene (University of
Chicago; Chicago, IL). Normal donkey serum, biotinylated donkey anti-rabbit
IgG (F(ab') 2 heavy and light chains), and purified rabbit gamma globulin were
obtained from Jackson ImmunoResearch Laboratories, Inc. (West Grove, PA).
The Vectastain Elite ABC immunoperoxidase kit was obtained from Vector
Laboratories, Inc. (Burlingame, CA).

Isolation and Culture of Peritoneal Macrophages
Female C57BL/ 6 mice (Harlan Laboratories, Indianapolis, IN) 9 to 12
weeks old were injected intraperitoneally with 1.5 ml of 10% Brewer's
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thioglycolate as previously described (Radzioch, Bottazzi, and Varesio 1987).
Four days later, animals were sacrificed and peritoneal lavage was performed.
6

Peritoneal exudate cells were plated at 2 X 10 cells per ml of phenol red-free
RPMI 1640 medium with 2% fetal bovine serum (FBS) and allowed to adhere.
After 2 hours, medium containing nonadherent cells was removed and replaced
with fresh medium.

The remaining cells were -95% macrophages, as

determined by Giemsa stain analysis. Macrophage cultures were "rested" for 48
hours prior to stimulation in order to diminish expression of cytokine genes
triggered by adherence to tissue culture plastic (Fuhlbrigge et al. 1987).

Culture of Macrophage Cell Lines
The ANA-1 murine macrophage cell line was obtained from Dr. Luigi
Varesio (Frederick Cancer Research and Development Center, National Cancer
Institute, Frederick, MD). The cell line was derived by infection of bone
marrow cells from a C57BL/ 6 male mouse with a recombinant retrovirus
containing the myc and raf proto oncogenes (Blasi et al. 1989). The J774A.1
murine macrophage cell line was derived from a female BALBI c mouse
(ATCC). All cell lines were maintained in RPMI 1640 medium with 5% FBS, 100
Units/ml penicillin, 100 mg/ml streptomycin and 2mM L-glutamine. Fortys
eight hours prior to stimulation, cells were plated at 5 X 10 cells per ml in
phenol red-free RPMI 1640 medium with 2% FBS in the absence of exogenous
stimulants. Cells were harvested for RNA isolation after 8 hours incubation,
unless otherwise specified.
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RNA Isolation and Northern Blot Analysis
Total RNA was isolated by a single-step guanidinium thiocyanatephenol-chloroform method (RNAzol B; Cinna Biotecx, Houston, TX) according
to manufacturer's specifications.

Northern blots, prepared as previously
32

described (Kovacs, Oppenheim, and Young 1986), were hybridized with Plabeled cDNA probes for JE and TNF-a. Quantitation of RNA signals was
performed by scanning densitometry using Ambis Quantprobe Software
version 3.02 (Ambis Systems, Inc.; San Diego, CA). All studies were performed
three times, unless otherwise stated.

Immunohistochemistry
Cytospin preparations of ANA-1 cells were examined for the presence of
estrogen receptor using the ER-21 rabbit polyclonal antibody. Cells were
immediately fixed in 4% paraformaldehyde for 10 minutes, washed in PBS for
15 minutes, and successively soaked in cold methanol and cold acetone at 4oc
for 3 minutes each. After rinsing in PBS, the slides were incubated with normal
donkey serum in PBS for 30 minutes to reduce nonspecific staining. The slides
were then incubated successively with the polyclonal rabbit anti-estrogen
receptor antibody, ER-21 (2 µg/ml) or with rabbit gamma globulin (2 µg/ml) as
a control antibody for 1 hour, and then with biotinylated donkey anti-rabbit IgG
for 30 minutes. Endogenous peroxidase activity was blocked for by incubation
for 10 minutes in 0.3% hydrogen peroxide (in PBS) prior to a 30 minute
incubation with Vectastain Elite ABC immunoperoxidase kit (1:100). Each
incubation was performed at room temperature in a humidified chamber and
followed by three 5-minute washes in PBS. Horseradish peroxidase enzyme
activity was detected by immersing the slides in 0.45 mg/ml diaminobenzidine
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(DAB) for a maximum of 15 minutes in buffer containing 0.15M NaCl, 0.05M
Tris, and 0.07%H20 2 • Slides were counterstained in methyl green and observed
by bright field microscopy.

Results

Expression of JE/MCP-1 mRNA in ANA-1
Cells
To determine when the peak level of JE/MCP-1 mRNA expression
occurred in ANA-1 cells, cultures were stimulated with 1 µg/ml LPS for 1, 3, 8,
or 18 hours, and Northern blot analysis was performed. Induction of JE/MCP-1
mRNA was detectable as early as early as 1 hour post-LPS stimulation (Figure
13, panel A). Because peak levels of the message were achieved at 8 hours after
LPS stimulation (see Table V), subsequent experiments were performed at this
time point, unless otherwise noted.
To determine the optimal concentration of LPS needed to induce
JE/MCP-1 mRNA expression, ANA-1 cells were stimulated with 10, 1, or 0.1
µg/ml LPS, and total cellular RNA was isolated for Northern blot analysis
(Figure 13, panel B). Unstimulated ANA-1 cells did not express JE/MCP-1
mRNA, whereas at all concentrations of LPS, a stronger signal was observed at
a concentration of 1 µg/ml LPS.

On the basis of these results, all other

experiments were performed by using 1 µg/ ml LPS.
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Table V: Densitometric Scan of Northern Blot of LPS-Induced JE mRNA
Expression in ANA-1 Murine Macrophages

Treatmene
None, lh
LPS (1 µg/ml), lh
None, 3h
LPS (1 µg /ml), 3h
None, Sh
LPS (1 µg /ml), Sh
None, 18h
LPS (1 µg /ml), 18h
None, Sh
LPS (10 µg /ml), Sh
LPS (1 µg /ml), Sh
LPS (0.1 µg /ml), Sh

IEmRNA
ODUnitsb
0
1.1
0
12.5
0

16
0

s
0
10
9.7

o.s

a ANA-1

murine macrophage cells were cultured in the presence of LPS as
described in Materials and Methods. The blot was hybridized with 32P-labeled
cDNA probes for murine JE.

bArbitrary units obtained from scanning densitometric analysis of x-ray filters.

E2 Inhibition of LPS-Induced JE mRNA Expression
To examine the effects of E2 on JE/MCP-1 mRNA expression in ANA-1
macrophages, cells were cultured in the absence of stimulants or with LPS (1
µg/ml), E 2 (3, 30, or 300 pg/ml), or in combination (Figure 14). As previously
shown, unstimulated ANA-1 cells did not express JE/MCP-1 mRNA (lane 1),
and LPS induced the expression of JE/MCP-1 mRNA (lane 2). Whereas E2
alone had no effect on expression of the message (lanes 3, 5, and 7), the
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Table VI: Densitometric Scan of Northern Blot of LPS-Induced JE and TNF-a
mRNA Expression in the Presence or Absence of E2

Treatment
None
LPS
E2 (3pg/ml)
LPS+ E2 (3pg/ml)
E2 (30 pg/ml)
LPS+ E2 (30pg/ml)
E2 (300pg/ml)
LPS + E2 (300pg/ml

IE
OD Units
1
109
19
105

TNF-a

% Inhibition

4

11

38
0
12

65
89

OD Units
0
8
0
8
1
6
1

% Inhibition

7

13

0
25

a ANA-1

murine macrophage cells were cultured in the presence of LPS (1
µg/ml) with or without the addition of 300 pg/ml of E2 or progesterone for 8
hours as described in Materials and Methods. The blot was hybridized with
32P-labeled cDNA probes for murine JE and TNF-a.
b Arbitrary

units obtained from scanning densitometric analysis of x-ray filters.

addition of increasing concentrations of E2 resulted in a dose-dependent
decrease in LPS-induced JE/MCP-1 mRNA expression (lanes 4, 6, and 8).
Typically, maximal inhibition was observed at 300pg/ml E2 and ranged from
approximately 50 to 90% ( see Table VI). These concentrations of E2 represent
the physiologic range of circulating E2 present in males and females during
different phases of the estrus cycle and in pregnancy (Carr 1990). The maximal
inhibition of JE/MCP-1 mRNA expression was specific for that cytokine, blots
were stripped and reprobed for analysis of expression of another
proinflammatory cytokine, TNF-a (Figure 14). Like JE/MCP-1, ANA-1 cells do
not spontaneously express TNF-a, but could be induced to express the message
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after stimulation with LPS. Treatment of ANA-1 macrophages with LPS and
low concentrations of E2 resulted in a slight decrease in TNF-a induction. This
slight decrease was not observed consistently as was the decrease in JE/MCP-1
mRNA expression. At higher doses of E2, LPS-induced stimulation of TNF-a
was enhanced relative to the level of expression triggered in culture of ANA-1
cells with LPS alone.

E2 Regulation of JE/MCP-1 mRNA Expression in
Other Macrophages
To determine whether E 2 inhibition of JE mRNA expression was unique
to the ANA-1 cell line, parallel experiments were performed using the J774A.1
macrophage cell line. Unstimulated J774A.1 cells did not express JE/MCP-1
mRNA, yet could be induced to express the message after stimulation with LPS.
As was observed with ANA-1 cells, untreated cells and E2 alone failed to affect
JE mRNA expression, while E2 treatment inhibited LPS-induced JE/MCP-1
mRNA expression of the message.
Similar observations were made using thioglycolate-elicited murine
peritoneal macrophages. Peritoneal macrophages were cultured for 8 hours in
the presence or absence of LPS and E2 (Figure 15). Untreated macrophages did
not express JE/MCP-1 mRNA, but could be induced to express the message
following LPS treatment. Although E2 alone had no effect on JE/MCP-1 mRNA
expression, it inhibited LPS-induced JE/MCP-1 mRNA expression (see Table
VII). E 2 suppression of LPS-induced JE/MCP-1 mRNA was also observed at 3
and 24 hours of culture, indicating that inhibition of JE/MCP-1 mRNA
expression was not merely caused by a change in the kinetics of expression of
the message.
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Table VII: Densitometric Scan of Northern Blot of LPS-Induced JE mRNA
Expression in the Presence or Absence of E2

Treatment3
None
LPS
E2 (300 pg/ml)
LPS+E2 (300 pg/ml)

JEmRNA
%Change
ODUnitsb
0
1.72
0
0.65

-62

3

Thioglycolate-elicited murine macrophage cells were cultured in the presence
of LPS (1 µg/ml) with or without the addition of 300 pg/ml of E2 for 8 hours as
32
described in Materials and Methods. The blot was hybridized with a Plabeled cDNA probe for murine JE.
bArbitrary units obtained from scanning densitometric analysis of x-ray filters.

In addition, treatment of LPS-stimulated peritoneal macrophages with
moxestrol, the

11-~-methoxy

derivative of ethinyl estradiol and a highly potent

estrogen, resulted in a decrease in JE/MCP-1 mRNA expression comparable
with that observed with addition of E2 (Figure 16). The specificity of moxestrol
for estrogen receptor and absence of cross-reactivity with other steroid
receptors (Raynaud et al. 1978) suggest that macrophages possess a high affinity
estrogen binding protein and that inhibition of JE/MCP-1 mRNA expression of
LPS-stimulated macrophages is mediated through this protein. To further
demonstrate that the observed effects could be mediated by the classical
estrogen receptor, thioglycolate-elicited murine peritoneal macrophages were
treated with LPS, E 2 , and the estrogen antagonist, tamoxifen, alone or in
combination. The addition of tamoxifen to LPS-treated macrophages reverses
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the E2 inhibition of JE/MCP-1 mRNA expression. Similar results were observed
in ANA-1 and J774A.1 cell lines.

Progesterone Fails to Inhibit Induction of JE mRNA
byLPS
To determine whether estrogen inhibition of JE mRNA expression is
specific for that steroid hormone, progesterone was added to ANA-1 cultures

Table VIII: Densitometric Scan of Northern Blot of LPS-Induced JE mRNA
Expression in the Presence or Absence of E2, Tamoxifen, or Moxestrol

JEmRNA

Treatment3
None
LPS
LPS+E2 (300 pg/ml)
Tamox. (300 ng/ml)
LPS+Tamox.
LPS+ E2+Tamox.
LPS+Mox. (300 pg/ml)

ODUnitsb
0
18.4
6.4
1
7.3
18.5
8.5

% Change

-65
-60
-65

a ANA-1

murine macrophage cells were cultured in the presence of LPS (1
µg/ml) with or without the addition of 300 pg/ml of E2, 300 ng/ml Tamoxifen,
or 300 pg/ml Moxestrol for 8 hours as described in Materials and Methods. The
blot was hybridized with a 32P-labeled cDNA probe for murine JE.
bArbitrary units obtained from scanning densitometric analysis of x-ray filters.
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Table IX: Densitometric Scan of Northern Blot of LPS-Induced JE and TNF-a
mRNA Expression in the Presence or Absence of E2 or Progesterone

ill

Treatment 3
None
LPS
E1
LPS + E2
Prog
LPS + Prog

ODUnitsb
1
191
0
68
0
203

%Change

-64
+6

TNF-a
%Change
ODUnitsb
0
9
1
19
+111
9
50
+456

3

ANA-1 murine macrophage cells were cultured in the presence of LPS (1
µg/ml) with or without the addition of 300 pg/ml of E2 or progesterone for 8
hours as described in Materials and Methods. The blot was hybridized with
32
P-labeled cDNA probes for murine JE and TNF-a.
bArbitrary units obtained from scanning densitometric analysis of x-ray filters.

alone or in combination with LPS (Figure 17). In contrast to E2, at 300 pg/ml,
progesterone did not inhibit JE/MCP-1 mRNA expression induced by LPS, but
rather appeared to enhance expression of the message.

Furthermore,

dihydroxytestosterone at the same concentration had no effect on LPS-induced
JE mRNA expression. As had been previously reported by others (Kawahara,
Deng, and Deuel 1991; Mukaida et al. 1991), dexamethasone inhibited LPSinduced JE mRNA expression. As shown in Figure 17, steroid regulation of
TNF-a mRNA expression after steroid hormone treatment does not follow the
same patterns as does JE/MCP-1. Whereas untreated cells do not express TNFa, exposure to LPS triggers expression of the message. Exposure to 300 pg/ ml
E2 fails to inhibit TNF-a mRNA expression in LPS-treated ANA-1 cells. In
contrast, like JE/MCP-1, treatment of cells with a combination of progesterone
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and LPS appears to enhance the level of expression of TNF-a above that of LPS
alone.

Detection of Estrogen Receptor in ANA-1 Cells by
Immunohistochemistry
In order to determine that the observed effects of E2 could be mediated
via the classical estrogen receptor (ER), we performed immunohistochemical
analyses, using the ER-21 antibody, to insure that estrogen receptors were
present in ANA-1 cells. With this antibody, cells positive for ER exhibit a strong
nuclear and diffuse cytoplasmic staining. As demonstrated in Figure 18, panel
A, ANA-1 cells stained positively for ER. Nearly all of the cells were positive,
with some cells more strongly labeled than others. In contrast, cells incubated
with a nonspecific antibody, rabbit gamma globulin (Figure 18, panel B) were
negative. These observations indicate that the ANA-1 murine macrophage cell
line, derived from a male C57BL/ 6 mouse, contains ER and is, therefore,
capable of responding to estrogen treatment.
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Discussion
The sexual dimorphism of the immune response is well documented
(Ansar-Ahmed, Penhale, and Talal 1985; Grossman 1985; Schuurs and Verhuel
1990), yet the role the sex steroid hormone, estrogen, plays in the regulation of
immune cell functions is only beginning to be understood. Connective tissue
disorders and autoimmune disease, such as scleroderma, lupus erythematosus,
and rheumatoid arthritis, are more prevalent in women of reproductive age
than in women of all ages and in men, and the severity of these disease states is
often altered during pregnancy (Czirjak et al. 1989; Holmdahl and Jansson 1988;
Steen 1990; Steen and Medsger 1990).

This is best demonstrated in

postmenopausal women receiving estrogen replacement therapy, in which
hormone replacement prevents bone loss (Christiansen 1993) and reduces the
risk of coronary artery disease (Knopp 1988). The above-mentioned conditions
involve local inflammatory reactions induced by immune cells and the
mediators
(including cytokines) that they release. Because these immune cell populations,
including monocytes, macrophages, lymphocytes, and mast cells, express
estrogen receptors (Cocchiara et al. 1990; Gulshan, McCruden, and Stimson
1990; Weusten et al. 1986), it suggests that estrogen could directly affect
cytokine production in these cells.
Chemotactic cytokines play an important role in initiating the tissue
repair process by recruiting immune and mesenchymal cells into a wound site
(Oppenheim et al. 1991).

Therefore, modulation of these mediators can

ultimately affect the outcome of the inflammatory response.

Because

macrophages play a central role in wound healing (Leibovich and Ross 1975),
the murine macrophage chemotactic factor, JE/MCP-1, plays a critical role in
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the wound healing response, as demonstrated by recent studies in which
JE/MCP-1 was shown to be present in fibrotic tissues, including pulmonary
fibrosis and atherosclerosis.

Glucan-induced pulmonary granulomatous

vasculitis in the rat was accompanied by an increase in the local expression of
MCP-1 mRNA and protein, with granuloma-associated alveolar macrophages
as the predominant source of MCP-1 in the later evolution of these lesions
(Flory, Jones, and Warren 1993). Administration of a neutralizing antibody
directed against MCP-1 resulted in decreased granuloma formation.
Furthermore, increased MCP-1 mRNA expression was observed in alveolar
macrophages during bleomycin-induced pulmonary fibrosis in the rat (Brieland
et al. 1993). MCP-1 was released from abdominal aortic aneurysms in greater
quantities than by explants from occlusive or normal aortas, and
immunohistochemical analysis revealed that the macrophage was the
predominant positive cell for MCP-1 in these explants (Koch et al. 1993).
We have recently found that administration of high physiologic levels of
E2 to ovariectomized mice inhibited abdominal connective tissue deposition in a
model of peritoneal adhesion formation triggered by i.p. injection of talc
(Frazier-Jessen et al., in press). In these studies, we observed that JE/MCP-1
mRNA levels in abdominal wall connective tissue were less in talc-treated
animals receiving estrogen replacement than in those given placebo, suggesting
that estrogen may modulate JE/MCP-l's role in regulatory recruitment of
macrophage to sites of inflammation and wound healing.
Herein, we report that physiologic levels of E2 can modulate expression
of JE/MCP-1 mRNA in vitro. this inhibition of LPS-induced JE/MCP-1 mRNA
expression occurs in primary culture peritoneal macrophages and macrophage
cell lines derived from both male and female mice. Our data suggest that

91
because macrophages from male and female mice respond similarly to E2
treatment, they express comparable levels of estrogen receptors, which is
consistent with the work of others (Gulshan, McCruden, and Stimson 1990;
Weusten et al. 1986). Thus, the observed differences between males and females
with regard to macrophage function are likely to result from differences in the
circulating estrogen levels that are several thousand-fold higher in females than
in males (Raynaud et al. 1978).
The fact that tamoxifen antagonizes the Erdependent inhibition of
JE/MCP-1 mRNA expression further suggests that the negative regulation of
expression of the message by estrogen is specific for that steroid hormone.
Because progesterone fails to block and, in fact, enhances LPS-induced
JE/MCP-1 mRNA expression, the effects of E2 on the expression of the JE/MCP1 gene are unique to estrogen. This observation is in accordance with the
observations of Kawahara and colleagues, demonstrating that progesterone is
unable to inhibit JE/MCP-1 mRNA expression in murine 3T3 fibroblasts
(Kawahara, Deng, and Deuel 1991). This is not surprising, as progesterone
often acts in opposition to estrogen.
Only a handful of studies have reported on the effects of gonadal steroids
on the expression of cytokine genes in purified immune cell populations. Hu
and coworkers showed that adherent peritoneal cells obtained from intact
female rats secreted greater amounts of IL-1 than cells from male or
ovariectomized female rats (Hu, Mitcho, and Rath 1988).

The increased

production of IL-1 was restored after E2 replacement in OVX animals.

IL-1~

mRNA expression in LPS-stimulated human monocytes was elevated
marginally in response to low physiologic levels of E 2 and inhibited markedly
after treatment with high doses of E2 (Polan et al. 1989). The doses required to
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diminish LPS-induced expression of IL-lP mRNA were 10-7 to 10-9 M E2 , well
above the physiologic range. The requirement for such high doses suggests that
E2 may not be utilizing specific high affinity receptors, but rather low affinity
estrogen binding sites reported to be present on peripheral blood mononuclear
cells (Ranelletti et al. 1988; Wada et al. 1992). At physiologic levels, E2 had
marked inhibitory effects on the production of TNF-a by human peripheral
blood mononuclear cells from postmenopausal women. This difference may be
caused by the relative level of estrogen receptors in cells from pre- and
postmenopausal women. Our studies show that JE/MCP-1 mRNA in LPSstimulated murine macrophages is inhibited by E2 in a dose-dependent manner
over a physiologic range of concentrations (10-11 to 10-9 M). In contrast, TNF-a
mRNA expression is not and, in fact, is enhanced by LPS-treated cells exposed
to high physiologic concentrations of E2 (10- 9 M). Taken together with our
observations, it should be clear that 1) cytokine mRNA expression can be
modulated by exposure of cells to estrogen and 2) not all cytokines are
coordinately regulated by the hormone. Differences between the studies of
others, cited above, and our work may be attributed to differences in the
species, the purity and state of activation of cell populations, and culture
conditions used in the studies.
Our studies do not address the mechanism(s) by which E2 regulates
JE/MCP-1 mRNA expression, because our immunoghistochemical anlaysis
show that the macrophages used in these studies have the classical estrogen
receptor and suggests that E2 suppression of expression of JE/MCP-1 mRNA
might be a result of ErER complexes binding to genomic estrogen response
elements (ERE), as has been reported in other systems. Although regions
homologous to the consensus sequence of the ERE have not been reported in
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the 5' flanking regions of the murine JE gene or the human MCP-1 genes, the
proximal promoter of the JE gene contains a silencer element that has not yet
been fully characterized (Freter et al. 1992). The presence of this element
suggests that, if ERE sequences are not found in the promoter, then E2 may
inhibit transcription of the JE gene by interacting with novel sequences.
It is likely that future studies will confirm that E2 inhibition of LPS

induction of JE/MCP-1 mRNA in macrophages is mediated by classical high
affinity estrogen receptors, because the concentrations of E2 used in these
studies are well within the range that utilizes this receptor. Alternatively, it is
also possible that other pathways of estrogen regulation of gene expression are
involved. For example, inositolphospholipid metabolism has been observed in
Erstimulated human endometrial fibrobalsts by a mechanism that does not
involve the classical estrogen receptor (Iida, Imai, and Tamaya 1989). Other
studies show that expression of JE/MCP-1 mRNA in macrophages is induced
by a combination of PMA, which activates protein kinase C, and calcium
ionophore A23187, which increases cytoplasmic Ca2+ levels (Introna et al. 1987).
Because LPS is known to mediate its effects on cytokine gene expression in
macrophages by triggering protein kinase C and calmodulin-dependent kinase
(Kovacs et al. 1989; Kovacs et al. 1988), the modulatory effects of E 2 on these
second messenger pathways could provide an additional mechanism by which
E2 could inhibit JE/MCP-1 mRNA expression.
In summary, our data demonstrate that at high physiologic levels, E2
inhibits LPS-induced JE/MCP-1 mRNA, and suggest that the local migration of
macropahges to wound sites may be impaired by E 2 • Interestingly, this
observations corresponds with sex steroid levels and the associated risk of
developing coronary artery disease. Estrogens protect against atherosclerosis in
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a wide variety of animal models, as well as in humans (Adams et al. 1991;
Barrett-Connor 1992; Knopp 1988; Stampfer et al. 1991). Even though estrogens
are able to induce changes of plasma lipid and lipoprotein levels (Sacks and
Walsh 1990; Schaefer et al. 1983; Walsh et al. 1991), this in itself does not fully
account for the prevention of atherosclerosis. On the basis of our results and
the observations of others, we propose that one possible mechanism for this
protective effect of estrogen involves its ability to inhibit JE/MCP-1 mRNA
expression by macrophages localized within the atherosclerotic plaque,
ultimately preventing the accumulation of more macrophages, the precursors of
the foam cells present within atherosclerotic lesions.

DISCUSSION

Peritoneal fibrosis and adhesion formation is the consequence of
overproduction of connective tissue within the peritoneal cavity. Currently, the
only therapy available for treatment of this potentially life-threatening
condition is surgical intervention to lyse adhesions. While several models of
adhesion formation exist (Diamond et al. 1991; Linsky et al. 1987; Myllarniemi et
al. 1966), the methods of assessment are crude at best and involve a large
amount of subjective interpretation.
One purpose for the studies presented herein was to develop a model of
peritoneal adhesion formation that allowed for more quantitative assessment of
the fibrotic response. Such a system would allow for testing of potential
therapeutic agents within the peritoneal cavity.

A successful therapeutic

regimen would decrease connective tissue deposition and may diminish the
need for further sugical lysing of adhesions.
The model developed in this dissertation involved the i.p. administration
of talc (hydrous magnesium silicate), once a common contaminant of surgical
gloves (Henderson et al. 1978; Kus et al. 1979). Other models of peritoneal
fibrosis have involved the use of assorted particulates, such as (Renvall, Lehto,
and Penttinen 1987) which is not cleared by the phagocytic cells of the immune
system, resulting in a chronic inflammatory stimulus. Surgical abrasion is
another commons means of eliciting chronic peritonitis (Diamond et al. 1991;
Linsky et al. 1987). Herein, talc was used to allow for the administration of
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different doses and, thus, the establishment of a dose-response relationship.
The results obtained form the first study (see Chapter 3) showed that i.p.
administration of talc caused a dose-dependent increase in connective tissue
deposition on the abdominal wall. From this curve we selected a talc dose
which generated detectable but not maximal adhesion thickness. Using this
mid range dose of talc alllowed us to detect both upward or downward
modulations following the addition of potentially therapeutic agents.

In

addition, the rank scoring analysis that had been previously reported in the
literature was performed (Myllarniemi et al. 1966). While this analysis gave a
crude measurement of the severity of adhesion formation, it did not allow for
detection of subtle differences between treatment groups, thus limiting its
usefulness as a critical diagnostic tool.
Estrogen is a gonadal steroid that has many as yet undescribed actions
upon the inflammatory response and connective tissue composition.
Replacement of estrogen in postmenopausal women remains an effective
treatment for the prevention of both osteoporosis and coronary artery disease
(Christiansen 1993) but little is known about the exact role of estrogen in normal
connective tissue homeostasis as it appears to function through poorly
understood mechanisms. Current animals models of human disease frequently
use male subjects in order to eliminate any confusion caused by cycling female
hormones (Dresser 1992). However, the usefullness of observations derived
from these studies is questionable, as physicians must prescribe treatment for
women of child-bearing age as well as men and postmenopausal women.
Furthermore, as recent epidemiological studies have shown that menstrual
cycle status at the time of mastectomy correlates with breast cancer recurrence
(Bluming and Hrushesky 1991), an understanding of the potential modulatory

97
affects of gonadal hormones on biological functions may be critical to the
success of the prescribed therapy.
Because of the potentially important effects of estrogen on inflammation
and wound healing, it was hypothesized that estrogen influenced the
inflammatory response and ultimately connective tissue compostion. We chose
to examine estrogen's potential effects in our model of talc-induced peritoneal
adhesion formation in the next set of experiments. The data from this second
study demonstrated that E2 administration to ovariectomized mice resulted in
inhibition of connective tissue deposition in the peritoneal cavity. The doses
administered were designed to deliver both low (30 pg/ml) and high (3000
pg/ml) circulatory levels of E2, representing serum proestrus levels and serum
levels comparable to the latter stages of pregnancy, respectively. Connective
tissue deposition in the peritoneal cavity was dose-dependently inhibited in
response to estrogen treatment. Interestingly, when the resultant connective
tissue thicknesses obtained from the first study (Figure 7) are compared with
those obtained from the second study (Figure 10), talc-treated (30 mg),
nonovariectomized mice had a mean connective tissue thickness that was
slightly lower than talc-treated ovariectomized mice.

This suggests that

removal of the ovaries, the major site of E2 synthesis, results in a
hyperresponsiveness to talc by way of increased connective tissue deposition. E2
is thought to mediate its actions by binding to intracellular receptors in target
cells and ultimately altering gene transcription. Clearly, a dramatic alteration in
circulating E2 could result in a different profile of such gene products, that are
either directly or indirectly are involved in inflammation and connective tissue
remodeling.

It has been known for many years that gonadectomy not only

increases body weight (Geiselman and Almli 1978), but eventually leads to
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thymic and splenic hypertrophy (Nandedkar 1992; Utsuyama and Hirokawa
1989). B and T lymphocyte populations increase in both spleen and bone
marrow as well as B lymphocyte precursors (Masuzawa et al. 1994; Utsuyama
and Hirokawa 1989). These observations suggest that E2 and other sex steroids
somehow control lymphocyte proliferation/ expansion and activation. In
response to E2 loss, an increase in both sheer number and activational status of
peripheral immune cell populations could conceivably shift the response to an
inflammatory stimulus to a more pathological outcome. Recent studies have
demonstrated that E2 levels in women are substantially reduced following
menopause and/ or surgical removal of ovaries which directly correlates with
an increased risk for development of both osteoporosis and coronary artery
disease. Concurrent with this is an observed increase in serum IL-1 and TNF-a
levels of these women (Pacifici et al. 1990; Ralston, Russell, and Gowen 1990).
Both IL-1 and TNF-a are intimately involved in connective tissue remodeling in
the bone microenvironment and the vascular system and excessive levels have
been associated with pathological changes. E 2 replacement by itself returns
serum IL-1 and TNF-a back to baseline circulating levels, while progesterone
replacement is ineffective. Thus our results and the observations of others
demonstrate an important role for E2 in normal immune function and
homeostasis.
Our in vivo studies did not address the potential immunomodulatory
effects of steroidal hormones besides E2 that are synthesized within the ovary.
We chose to focus on E2, as it is the major steroidal product of the ovary. Other
potentially relevant hormones include progesterone, testosterone (a precursor
in estrogen synthesis), and dihydroepiandrostenedione (DHEA).

In the

reproductive tissues, progesterone typically has opposing activities in contrast
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to estrogen. Also, as stated earlier, progesterone replacement alone does not
improve cardiovascular outcome nor risk of osteoporosis in women at
menopause nor after surgical ovariectomy (Christiansen 1993). Progesterone is
also not able to reduce increased circulating TNF-a/IL-1 levels in these women
(Pacifici et al. 1990; Ralston, Russell, and Gowen 1990). DHEA levels decrease
as individuals age and several recent studies have shown a direct correlation of
immune function in aged versus young animals (Weksler 1993). Thus, our
results cannot discount that these other steroids may play a role in connective
tissue remodeling.
In addition, the cells in the peritoneal cavity may not be involved in the
deposition of connective tissue to the same extent as cells that have already
migrated to the wound site. The latter population of cells can directly influence
the local wound site by secreting cytokines which influence the production of
extracellular matrix molecules by fibroblasts. In order to address this issue, we
performed immunohistochemical analyses on abdominal wall tissue using the
F4/80 monoclonal antibody, a specific marker for cells of the macrophage
lineage (Hume, Loutit, and Gordon 1984; Hume et al. 1983). While these
experiments revealed that macrophages were present in high numbers in
adhesion tissue, the number of macrophages per area of adhesion/ connective
tissue did not differ between talc-treated animals receiving estrogen versus
those that did not receive estrogen, even though the amount of connective
tissue deposited in these animals did differ. We further demonstrated the
expression of the monocyte chemoattractant protein, JE, in abdominal tissues
taken from talc-treated mice and that JE mRNA was not expressed in talctreated mice receiving E 2 replacement, suggesting a mechanism for our
observations. Since macrophages are present in the adhesion tissue of our
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peritoneal model, it is likely that they play an active role in the development of
these adhesions, confirming previous observations that these cells are key
players in the resolution of wound healing (Leibovich and Ross 1975).
To monitor peritoneal adhesion formation, animals were sacrificed on
day 14 post-talc injection, since preliminary histological studies revealed that
fibrin present in adhesion tissue in response to i.p. talc administration was not
converted to collagen, as detected by trichrome staining, (MR Frazier-Jessen,
unpublished observation) until day 14. To begin to examine mechanisms which
could explain extrogen mediated effects on connective tissue deposition, we
monitored peritoneal cell populations. This analysis at day 14 did not reveal
any differences between talc-treated and saline controls animals. While these
results were disappointing in view of the differences in connective tissue
accumulation in the treatment groups, there are several factors that could
explain our observations. One such possibility involves the kinetics of cellular
migration in response to an inflammatory stimulus which follows essentially
the same pattern irregardless of the tissue I organ.

Typically, there is an

immediate recruitment of inflammatory cells to the site of injury. The first cells
to arrive at the site consist mainly of neutrophils. If the neutrophil population is
unable to clear the irritant, macrophages are elicited to the site of inflammation.
In instances of chronic inflammation, lymphocytes are eventually recruited into

the tissue site.

However, while observation about changes in leukocyte

populations might be better addressed at an earlier timepoint in this model,
assessment of connective tissue deposition could not be determined at such an
early timepoint. In addition, randomly cycling female mice were used in this
first study. As demonstrated by our subsequent studies, sex steroids can
greatly influence inflammatory outcomes. While not performed, a comparison
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of estrus cycle status with leukocyte populations might have yielded more
significant differences. Finally, one of the unforeseen complications resulting
from i.p. talc injection was that analysis of total cell numbers present within the
peritoneal cavity was difficult to monitor, because adhesion prevented
collection of cells, especially following administration of higher doses of talc.
Accurate information would have been useful in gaging the magnitude of
inflammation elicited and/ or total increases in leukocyte populations.
In the final study, an examination of a possible mechanism by which E2
might be inhibiting connective tissue deposition was performed. As previously
discussed, macrophages are critical to the wound healing response and they
have been linked to the development of peritoneal adhesions and fibrosis in
numerous abdominal pathologies (Kovacs 1991; Leibovich and Ross 1975;
Simons et al. 1992). Therefore, it was hypothesized that recruitment of these
macrophages is a key factor in the outcome of the inflammatory response and
studies were conducted to determine whether E2 could modulate JE (murine
homologue of MCP-1) mRNA expression in murine macrophages in vitro. This
investigation revealed that E2 inhibited JE mRNA expression triggered by LPS
or talc stimulation in several macrophage cell lines and in thioglycolate-elicited
murine peritoneal macrophages. This effect was dose-dependent, with maximal
inhibition occurring at 300 pg/ml. Furthermore, this inhibition was specific for
estrogen in that progesterone and DHT did not inhibit JE mRNA expression.
An estrogen agonist, moxestrol, also inhibited JE mRNA expression and an
estrogen antagonist, tamoxifen, was able to reverse this inhibition.
Immunohistochemical analysis revealed that the classical ER are present in
macrophages, confirming the work of others (Gulshan, McCruden, and Stimson
1990; Weusten et al. 1986). Since the concentrations of estrogen used in these
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studies are well within the range utilized by this receptor, it suggests that the
observed phenomena were mediated through the classical estrogen receptor.
The exact mechanism by which E2 inhibits JE mRNA expression is not
known and was not addressed in this dissertation. While regions homologous
to the consensus sequence of the estrogen response elements (ERE) have not
been reported in the JE promoter, several "ERE-like" elements have been
identified in the 5' flanking regions of murine, rat, and human JE/MCP-1 genes
(A. Weisz, unpublished observation). In addition, the proximal promoter of the
JE gene contains a silencer element, which has yet to be characterized (C.D.
Stiles, personal communication), suggesting that, if functioning ERE sequences
are not found, E2 may inhibit transcription of the JE gene by interacting with
novel sequences in the silencer element.
Alternatively, it is possible that E2 suppression of JE mRNA expression
involves blocking the second messenger pathways that lead to induction of
expression of the message rather than activating an antagonistic pathway.
Elevation of intracellular cyclic AMP (cAMP) has been shown to suppress LPSinduced JE mRNA expression in macrophages (Tannenbaum and Hamilton
1989) and, therefore, it is possible that E2 inhibition of JE mRNA expression
results from elevation of cAMP levels. Finally, E2 /ER complexes may interfere
with the binding of cis-acting proteins to genomic elements that are known to
be present in the 5' flanking region of the JE gene. The ERE of the human c-fos
gene binds the E2 /ER complex and the AP-1 transcription factor (Weisz and
Rosales 1990), suggesting that E 2 regulation of the JE gene may be accomplished
by a similar mechanism. This idea is further supported by the observation that
the rat JE promoter contains an AP-1 binding site (Timmers et al. 1990). Future
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experiments directed at these possibilities will help to determine the mechanism
of inhibition of JE gene expression by E2 •

SUMMARY

In conclusion, the studies presented in this dissertation show that
estrogen inhibits connective tissue deposition in a murine model of peritoneal
adhesion formation and one possible mechanism that was examined in this
dissertation is the inhibition of monocyte/macrophage chemotaxis via the
inhibition of JE mRNA expression by peritoneal macrophages (see Figures 19
and 20). Since estrogen appears to have inhibitory effects connective tissue
deposition, the results obtained from these studies have clinical relevance in the
treatment of patients with fibrotic disorders, such as peritoneal fibrosis and
atherosclerosis. Conversely, if inhibition of estrogen proves to enhance wound
healing, then patients with poor healing characteristics, such as individuals
with cutaneous ulcers, could be given antiestrogens in order to maximize their
wound healing response. Finally, these studies further emphasize that it is
important for clinicians to take into consideration a patient's hormonal status
when considering treatment regimens.
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Figure 19. Proposed Effect of E2 on JE mRNA Synthesis in Macrophages. In
response to an inflammatory stimulus (such as talc or LPS) JE gene expression is
upregulated, leading to synthesis of JE protein. In the presence of elevated E2
levels, the expression of the JE gene is inhibited.
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Figure 20. Proposed Effect of E2 on Monocyte/Macrophage Chemotaxis in the
Peritoneal Cavity. (A) In response to an inflammatory stimulus, monocytes are
recruited via the release of chemotactic factors such as JE. (B) In the presence of
elevated E2 levels, secretion of JE is decreased, resulting in a decreased
recruitment of monocytes/macrophages to the site of inflammation.
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